

May 24, 2024

CURRICULUM VITAE
STEPHANIE L. GRAFF, MD, FACP, FASCO

593 Eddy Street, George 3
Providence, Rhode Island 02903
401-444-5388
401-444-4184

SGraff1@Lifespan.org

Social Media: Twitter: @DrSGraff

Instagram: DrSGraff

Co-Administrator, Hematology Oncology Women's Physician's Group, 2015-

Co-Administrator of @HemOncWomenDocs Twitter 2017-

EDUCATION

Undergraduate

University of Missouri-Kansas City, Liberal Arts,
Bachelor of Liberal Arts, 1998-2003

Medical School

University of Missouri-Kansas City School of
Medicine, 1998-2004, MD 2004

POSTGRADUATE TRAINING

Residency

University of Missouri – Kansas City School of
Medicine, 2411 Holmes Street, Kansas City,
Missouri 64108, Internal Medicine, 2004-2007

University of Missouri – Kansas City School of
Medicine, 2411 Holmes Street, Kansas City,
Missouri 64108, Internal Medicine Chief
Residency, 2007-2008

Fellowship

University of Kansas School of Medicine, 3901
Rainbow Boulevard, Kansas City, KS 66160,
Medical Oncology & Hematology Fellow, 2008-
2011 with Breast Oncology sub-fellowship 2010-
2011

Post-Graduate

American Society of Clinical Oncology Leadership
Development Program, 2318 Mill Road, Suite 800 |
Alexandria, VA 22314, June 2019-2021

POSTGRADUATE HONORS AND AWARDS

Girl Scout Gold Award, 1997

Gold Humanism Honor Society, The Arnold P. Gold Foundation, May 2007

Sirridge Award (for Outstanding Clinical Performance), University of Missouri Kansas City School
of Medicine Internal Medicine Residency Program, June 2007

Frist Humanitarian Award, HCA Midwest Health Research Medical Center, May 2017

Ingram's Top Doctors, Ingram's Magazine, Kansas City, MO, October 2017
 Fellow of the American College of Physicians (FACP), November 2018
 APEX Award for Publication Excellence, Social Media - Best Single Blog Post. Communications Concepts, 2019
 Women Leader in Oncology Nominee, Women Leaders in Oncology® 8th Annual Women Leaders in Oncology Reception, June 2021
 Benjamin L. Sapers, MD Memorial Award, American College of Physicians, Rhode Island Chapter, awarded to "an outstanding teacher, scholar with characteristic academic rigor and exchange, and evidence of empathy and humanism, superlative communication with patients and families", Awarded March 2022
 Excellence in Mentorship Award, Brown University Hematology Oncology Fellowship Program, Brown Alpert Medical School, Awarded June 2022
 Woman Disruptor of the Year, Healio® Disruptive Innovators 2022. Awarded to "a woman in the field of hematology/oncology who emerged as a leader and an example to younger of how a successful career can unfold. Awardee has had career of positive disruption and positive impact within specialty." Awarded June 2022
 APEX Award for Publication Excellence, Social Media – Single Blog Post. Communications Concepts, 2022
 GRASP Advocate Choice Award, in memory of Rhonda Mullins, San Antonio Breast Cancer Symposium 2023 for **Graff SL**, Freeman E, Roach M, Wilson R, Fairley R, Guallatte M, Stemland J, Chan B, Wochal P, Katz J, May-Slater S. Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making: Experiences and Perspectives of Patients, Caregivers, and Clinicians
 Fellow of the American Society of Clinical Oncology (FASCO), February 2024
 Master of Arts *ad eundem*, Brown University, May 26, 2024
 American Society of Clinical Oncology 2023 Advocacy Champion, Speaker's Circle, awarded April 2024

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Medical License, State of Missouri, #2006006489, 2004 (Not active)
 Medical License, State of Kansas, #04-32923, 2008 (Not active)
 2018 American Board of Internal Medicine, Diplomat in Hematology, 2011;
 Maintenance of Certification in good standing, 2023
 American Board of Internal Medicine, Diplomat in Medical Oncology, 2011; Maintenance of Certification in good standing, 2023
 American Board of Internal Medicine, Diplomat in Internal Medicine, 2007; 10-year Recertification 2017
 Medical License, State of Rhode Island, #17458, 2021-

ACADEMIC APPOINTMENTS

Assistant Professor, Department of Medicine, Warren Alpert Medical School, Brown University, June 2021-July 2023
 Director of Breast Oncology, Lifespan Cancer Institute, Providence, Rhode Island, 2021-
 Arts & Medicine Track, Internal Medicine and Medicine-Pediatrics Residency Program, Brown University, Faculty & Mentor, 2022-
 Mentor, Doctoring Mentor Program, Warren Alpert Medical School, Brown University, 2022-
 Associate Professor, Department of Medicine, Warren Alpert Medical School, Brown

University, July 2023-

HOSPITAL APPOINTMENTS

Attending Physician, Department of Internal Medicine, St. Luke's Hospital, Kansas City, Missouri 2007-2008
 Breast Oncologist, Sarah Cannon Cancer Institutes (Midwest Cancer Care), HCA Midwest, Kansas City metropolitan area, Kansas and Missouri, 2011- 2021.
 National Breast Lead, Clinical Programs, Sarah Cannon Cancer Institute Network, Nashville, Tennessee, 2016- 2021.
 Director, Breast Program, Sarah Cannon Cancer Institute at HCA Midwest Health, Kansas City, Missouri. 2016- 2021.
 Associate Director, Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, Tennessee, 2017- 2021
 Director, Clinical Research Program, Sarah Cannon Cancer Institute at HCA Midwest Health, Kansas City, Missouri. 2020-2021
 Director of Breast Oncology, Lifespan Cancer Institute, Providence, Rhode Island, 2021-

OTHER APPOINTMENTS

Editorial Positions

Associate Editor

Cancer Medicine, Breast & Gynecologic Oncology, 2022-2023

Section Editor

Missouri Medicine, Hematology & Medical Oncology, 2019- 2021

Editorial Board

Oncology Times, Chair, 2023-

Journal of Clinical Oncology, Art of Oncology, 2023-2025

Healio Women in Medicine Board, 2021-

American Journal of Clinical Oncology, 2021 -

Ad hoc Reviewer:

Journal of Clinical Oncology, 2018-

Journal of Oncology Practice, 2018-

Journal of the National Cancer Institute, 2020-

Breast Cancer Research and Treatment, 2021-

Nature Medicine, 2022-

"ASCO Reading Room" for *MedPageToday*, 2021 –

Cancer, 2022-

New England Journal of Medicine, 2023-

The BMJ, 2023-

HOSPITAL COMMITTEES

Performance Improvement Committee, Research Medical Center, 2012 - 2014
 Oncology Evidence Based Order Set Committee, HCA Healthcare, Nashville 2011-2012
 Breast Program Leadership Committee, Chair, Centerpoint Medical Center, 2012- 2012
 Institutional Review Board, HCA Midwest Health System, 2012 - 2013
 Commission on Cancer Committee, Research Medical Center, Kansas City, 2012 - 2015
 Commission on Cancer Committee, Vice-Chair: HCA Midwest Health Division, 2016 - 2021
 National Accreditation Program for Breast Centers (NAPBC) Breast Program Leadership Committee Chair, Research Medical Center; 2011-2021

National Accreditation Program for Breast Centers (NAPBC) Breast Program Leadership Committee member, Menorah Medical Center, 2013-2021
 Kansas City Cancer Governance Board, HCA Midwest Health System/Sarah Cannon Cancer Institute, 2013-present
 Breast Workgroup, HCA Midwest Health System/Sarah Cannon Cancer Institute, Chair 2013-present
 Health Outcomes Research Steering Committee, Sarah Cannon Research Institute, Member, 2017-2021
 Breast Steering Committee, Lifespan Cancer Institute, Member, June 2021-
 Scientific Review & Monitoring Committee, Lifespan Office of Cancer Research, Lifespan Cancer Institute, Member, July 2021- ; Expedited Reviewer, March 2022 -
 Lifespan Cancer Institute Executive Committee, July 2021-
 Search Committee, Breast & GYN Oncologist search, Chair, July 2021- January 2022
 Lifespan Cancer Institute Multidisciplinary Tumor Board, Chair, January 2022-
 Lifespan Cancer Institute Breast Cancer Strategic Retreat, Lead, April 2022
 Lifespan Cancer Institute Operations Council, October 2022 -
 2023 Day of Giving Executive Committee, Rhode Island Hospital, November 2022 – March 2023
 Search Committee, Breast & GYN Oncologist search, Chair, November 2023—

UNIVERSITY COMMITTEES

Evaluations and Competency Committee, University of Missouri-Kansas City Internal Medicine Residency, 2006 - 2008
 Internal Medicine Residency Committee, University of Missouri-Kansas City Internal Medicine Residency, 2007 - 2008
 Leadership Committee, University of Missouri-Kansas City Internal Medicine Residency, 2006 - 2008
 Circulating Tumor Cells Working Group, University of Kansas Cancer Center, 2009 – 2010
 Co-Lead, Breast Cancer Translational Research Disease Group (TRDG), Legorreta Cancer Center at Brown University, June 2021-April 2025
 Search Committee, Breast & GYN Oncologist search, Chair, Brown University, July 2021- January 2022
 Joint Program in Cancer Biology Search Committee, Member, Brown University, July 2021-
 Breast & GYN Malignancy Journal Club Co-Chair, Twitter Spaces, Legorreta Cancer Center at Brown University, August 2021- June 2023
 Co-Chair, Brown University Oncology Cooperative Group (BrUOG) Breast Committee, November 2021-
 Center for Interdisciplinary Translational Cancer Research Grant Review Committee, Brown University, January 2022
 Search Committee, Immuno-Oncologist, Brown BioMed Department of Medicine, Diversity Representative, July 2022-
 Legorreta Cancer Center Data Science Working Group, Brown University, December 2022 –
 Legorreta Cancer Center Cancer Therapeutics Program, Brown University, March 2022 –
 Medical Faculty Executive Committee, Brown University, 2023 –
 Institutional Review Board Collaborative Research Engagement Workgroup (CREW), January 2024 –
 Legorreta Cancer Center Leadership Advisory Group, Brown University, January 2024-
 Legorreta Cancer Center American Cancer Society Institutional Review Grant Committee,

February 2024

Co-Director, Breast Cancer Translational Research Disease Group (TRDG), Legorreta
Cancer Center at Brown University, April 2024-

NATIONAL COMMITTEES

Regional Steering Committee, Americas Region MonarchE Clinical Trial, Endocrine Therapy
With or Without Abemaciclib (LY2835219) Following Surgery in Participants With
Breast Cancer (monarchE) NCT03155997, Eli-Lilly, July 2018-2021

Collaboration for Outcomes using Social Media in Oncology (COSMO), June 2021-

SWOG Community Chair, “STOP CIPN: Randomized Trial of Limb Cryocompression versus
Continuous Compression versus Low Cyclic Compression for the Prevention of Taxane
Induced Peripheral Neuropathy (SWOG-S2205), NCT05642611, Funded by National
Cancer Institute US NIH Grant UG1CA189974, March 2022-

The American Cancer Society National Breast Cancer Roundtable (ACS NBCRT), American
Society of Clinical Oncology Representative, Risk Reduction, Screening, and Early
Detection Priority Workgroup, March 2023-

National Fellows Forum Chair—Breast Cancer, San Antonio Breast Cancer Symposium with
OnLive, Faculty, August 2023-December 2023

INTERNATIONAL COMMITTEES

Global Manuscript Committee, Evaluation of Lasofoxifene versus Fulvestrant in Advanced or
Metastatic ER+/HER2- Breast Cancer With An ESR1 Mutation (ELAINE-1),
NCT03781063, Sermonix Pharmaceuticals, July 2022-

Global Steering Committee, postMONARCH: A Randomized, Double-Blind, Placebo-
Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to
Placebo plus Fulvestrant in Participants with HR+, HER2, Advanced or Metastatic Breast
Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy, I3Y-
MC-JPEF, NCT05169567, December 2021 -

Translational Science Steering Committee, MonarchE Clinical Trial, Endocrine Therapy With or
Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast
Cancer (monarchE) NCT03155997, Eli-Lilly, September 2022-

Global Steering Committee, A Phase III, Open-label, Randomised Study of Datopotamab
Deruxtecan (Dato-DXd) in combination with Durvalumab compared with
Pembrolizumab in combination with Investigator’s Choice of Chemotherapy
(Paclitaxel/Nab-paclitaxel/Gemcitabine+Carboplatin) in Patients with PDL1 positive
Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
(TROPIONBreast05, NCT06103864), Astra-Zeneca, January 2023-

Co-Chair, Global Steering Committee, A phase IIIb study to characterize the effectiveness and
safety of Adjuvant ribociclib in broader and closer to real-World patient populations in
stage II and stage III Early breast cancer (ADJUVANT WIDER), Novartis, January
2023-

Abemaciclib and Imlunestrant Metastatic Breast Cancer Translational Steering Committee,
Lilly, September 2023-

MEMBERSHIP IN SOCIETIES

American Society of Clinical Oncology (ASCO), 2009-

ASCO University™ Fellows Advisory Group: 2009 - 2011.

ASCO Women in Oncology Strategic Planning Workgroup, 2017

ASCO Clinical Practice Guideline Implementation Network, Member, December 2017-
 ASCO Professional Development Committee, 2018- 2019. Women in Oncology
 subcommittee, 2018- 2019.
 ASCO Research Community Forum, 2018- 2021; Site Qualifications Working Group,
 2018- 2021
 ASCO Annual Meeting Women’s Networking Center Mentor, 2019-
 ASCO Annual Meeting Women’s Networking Center Planning Committee, 2020
 ASCO Advantage, Alexandria VA
 Course Director, with Cancer.Net “Cancer Basics for People With Cancer,
 Survivors, and the Public,” November 2019
 Course Director, “Breast Cancer”, April 2020 (Virtual)
 Course Director, “Breast Cancer”, February 2021 (Virtual)
 Course Director, “Breast & Lung Cancer”, August 2021
 Course Director, “Breast Cancer”, Alexandria VA, January 2023
 ASCO Quality of Care Council, 2020- 2021
 ASCO Women In Oncology Working Group, 2020-2022
 ASCO Joint Certifications Committee, 2021-2023
 ASCO Advocacy Summit, Volunteer: May 2023, April 2024 (ASCO Advocacy
 Champion—Speaker’s Circle)
 ASCO Expert Answers, 2023
 Developed Course Content and Recorded CME Module on “How do I treat
 refractory metastatic HR+/HER2- breast cancer”
 American Cancer Society National Breast Cancer Roundtable, ASCO Representative,
 Risk Reduction Workgroup Member, 2023-2024
 ASCO Patient-Clinician Communication Guideline Consensus Panel, May 2023 –
 ASCO Drug Shortages Working Group and Breast Cancer Drug Shortages Working
 Group: Carboplatin/Cisplatin, May 2023 – July 2023
 American College of Physicians (ACP), 2017-
 Rhode Island American College of Physicians 2023 Annual Meeting Planning
 Committee, 2022-
 American Association for Cancer Research (AACR), 2017-
 AACR, University of Texas Health San Antonio MD Anderson, San Antonio Breast Cancer
 Symposium Communications Team “San Antonio Breast Cancer Symposium 2023
 Social Media Supporter,” December 2023
 Association of Clinical Research Professionals (ACRP), 2020-
 European Society of Medical Oncology (ESMO), 2021-
 SWOG Cancer Research Network, October 2021-
 SWOG Digital Engagement Committee, October 2021-
 Principal Investigator, Lifespan Cancer Institute – Organizational Lead Principal
 Investigator, April 2022-
 Breast Committee, April 2022-
 SWOG Study Co-Chair, “Phase 3 Trial of Sequencing Antibody Drug Conjugates
 (ADCs) and OptimizinG Outcomes in HER2-Low Advanced/MEtastatic
 Breast Cancer (SAGE; SWOG-S2413), December 2022-November 2023,
 Non-Funded by NCI Breast Cancer Steering Committee (BCSC)
 Breast Committee Retreat, Fall 2023 SWOG Meeting, Chicago IL
 Early Drug Development and Rare Cancers Committee, April 2022-

Liaison Early Drug Development and Rare Cancers Committee to the Breast Committee, April 2022-
 Alliance for Clinical Trials in Oncology, October 2021-
 The Alliance for Clinical Trials in Oncology Breast Cancer Committee, October 2021-
 National Consortium of Breast Centers, 2021-
 Primary Contact, Institutional Member, 2022-
 Clinical Track Committee, 2022-
 High-Risk Workshop Sub-Committee, 2022- present; Chair, 2023 - present
 Multinational Association of Supportive Care in Cancer, 2023-
 Oncodermatology Study Group, 2023-
 Mucositis Study Group, 2023-
 Neurologic Complications Study Group, 2023-
 Rhode Island Medical Women's Association, Member, 2024-

OTHER KEY APPOINTMENTS

Gilda's Club Professional Resource Council: Gilda's Club Kansas City, 2011- 2021
 The Research Foundation, 2012-2021
 Research Foundation Board, member, 2019-2021,
 Research Foundation Board Finance subcommittee, 2019- 2021
 Research Foundation Bixby Symposium Director, 2020
 Chair, Research Foundation Cancer Symposium, 2013
 Research Foundation, Candlelight Ball Steering Committee, 2012- 2012
 Male Breast Cancer Coalition, Volunteer, 2017-
 American Cancer Society, 2018-
 American Cancer Society, New England/Rhode Island Leadership Council, August 2021-
 April 2024
 American Cancer Society, Kansas/Kansas City Area Board, Chair 2020-2021, Vice Chair
 November 2019-2020, Board Member April 2018-May 2021
 American Cancer Society National Breast Cancer Roundtable, 2023-
 ASCO Representative, Risk Reduction, Screening, and Early Detection Priority
 Workgroup Member, 2023-2024
 Steering Committee, 2024 - 2026
 Medical Advisor, Dr. Susan Love Foundation for Breast Cancer Research, September 2020-
 May 2024
 11th International Symposium on the Human Breast Planning Committee, June 2022-
 February 2023
 Grant Review Committee, \$20,000 Sharon D. Lund Foundation Grant
 Grant Review Committee, \$75,000 Gilead Oncology Foundation Grant for Triple
 Negative Breast Cancer In Black Women
 Study Medical Lead, Clinical Meaningfulness in Metastatic Breast Cancer, in partnership
 with PRECISIONheor and Gilead Oncology
 Caris Precision Oncology Alliance,
 Healthcare Disparities Council, June 2021-
 Breast Disease Group, June 2021- , Chair-Elect June 2021-22, Chair June 2022-
 June 2024
 St. Gallen's Breast Cancer Conference Social Media Scientific Editor, 2023
 Rhode Island American Society of Clinical Oncology State Affiliate (RIOS) Charter Initiative
 Executive Leadership Co-Chair, May 2023 –

Medical and Scientific Advisory Council, Male Breast Cancer Global Alliance, January 2024 –
 Worldwide Innovative Network (WIN), Co-Moderator, Breast Cancer Molecular Tumor Board,
 January 2024—
 Dempsey Center for Quality Cancer Care, Board of Directors, February 2024 -

FUNDED PROJECTS

1. Racial Disparities in Triple Negative Breast Cancer: Syngeneic mice models, \$100,000 Laboratory Research Project. (Funder: Grace Hortense Greenley Trust Grant, directed by The Research Foundation in memory of Eva Lee Caldwell), Co-Investigator Dr. Suman Kambhampati. Funded laboratory work at KC Veterans Affairs hospital looking at racial disparities in syngeneic mice models with triple negative breast cancer in partnership with Banerjee S, Banerjee SK. 11/2017- 2019.
2. Prevention of datopotamab deruxtecan (TROP-2 directed ADC) Stomatitis in patients with HER2-negative metastatic breast cancer using Dexamethasone cryotherapy Mouthwash: a single-arm, phase 2 trial (TROPION-DM), Brown University Oncology Cooperative Group Trial # 431; \$1,200,000 Investigator initiated trial (Funder: Daiichi Sankyo) Principal Investigator. Primary Objective: Reduce incidence of all grade stomatitis; 07/2023 - Completion of enrollment.

PUBLICATIONS LIST

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Gupta V, Haque I, Chakraborty J, **Graff SL**, Banerjee S, Banerjee SK. Racial disparity in breast cancer: can it be mattered for prognosis and therapy. *J Cell Commun Signal*. 2018 Mar;12(1):119-132. doi: 10.1007/s12079-017-0416-4. Epub 2017 Nov 29. PMID: 29188479; PMCID: PMC5842180.
2. Ghosh A, Sarkar S, Banerjee S, Behbod F, Tawfik O, McGregor D, **Graff SL**, Banerjee SK. MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis. *PLoS One*. 2018 May 29;13(5):e0198143. doi: 10.1371/journal.pone.0198143. PMID: 29813119; PMCID: PMC5973560.
3. Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, **Graff SL**, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. *J Clin Oncol*. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22. PMID: 29787356.
4. **Graff SL**, Close J, Cole S, Matt-Amaral L, Beg R, Markham MJ. Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians. *J Oncol Pract*. 2018 Dec;14(12):e758-e769. doi: 10.1200/JOP.18.00448. PMID: 30537459.
5. Duma N, Durani U, Woods CB, Kankeu Fonkoua LA, Cook JM, Wee C, Fuentes HE, Gonzalez-Velez M, Murphy MC, Jain S, Marshall AL, **Graff SL**, Knoll MA. Evaluating Unconscious Bias: Speaker Introductions at an International Oncology Conference. *J Clin Oncol*. 2019 Dec 20;37(36):3538-3545. doi: 10.1200/JCO.19.01608. Epub 2019 Oct 11. PMID: 31603705
6. Woitowich NC, **Graff SL**, Swaroop M, Jain S. Gender-Specific Conferences and Symposia: A Putative Support Structure for Female Physicians. *J Womens Health*

- (Larchmt). 2020 Aug;29(8):1136-1141. doi: 10.1089/jwh.2019.7859. Epub 2019 Nov 7. PMID: 31697577.
7. **Graff SL**, Holder JM, Sears LE, Kurbegov D. Increase in Genetic Counseling and Testing Referrals After Breast Cancer Pathway Implementation. *JCO Oncol Pract*. 2020 Dec;16(12):e1481-e1488. doi: 10.1200/JOP.19.00552. Epub 2020 Jul 10. PMID: 32650693.
 8. Denduluri N, Somerfield MR, Chavez-MacGregor M, Comander AH, Dayao Z, Eisen A, Freedman RA, Gopalakrishnan R, **Graff SL**, Hassett MJ, King TA, Lyman GH, Maupin GR, Nunes R, Perkins CL, Telli ML, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. *J Clin Oncol*. 2021 Feb 20;39(6):685-693. doi: 10.1200/JCO.20.02510. Epub 2020 Oct 20. PMID: 33079579.
 9. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; **monarchE Committee Members and Investigators**. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *J Clin Oncol*. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20. PMID: 32954927; PMCID: PMC7768339.
MonarchE Regional Steering Committee Members: Abuin GG, Lim E, Santi P, Hegg R, Liao N, Christiansen B, Eigeliene N, Martin-Babau J, Ettl J, Mavroudis D, Chiu J, Lam PF, Boer K, Agarwal A, Nagarkar R, Paluch-Shimon S, Moscetti L, Sagara Y, Kim S-B, Maciel MM, Tjan-Heijnen V, Broom R, Dolnoslaskie AL, Schenker M, Volkov N, Yap YS, Coccia-Portugal M, García Sáenz JA, Andersson A, Chao T-Y, Gokmen E, Harputluoglu H, Berzoy O, Patt D, McArthur H, Chew H, Chalasani P, Kaufman P, **Graff S**.
 10. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Lorient Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; **KEYNOTE-361 Investigators**. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. PMID: 34051178.
KEYNOTE-361 Investigators: Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, David Hugo Flores, Agustin Falco, Matias Molina, Filip Van Aelst, Christof Vulsteke, Briec Sautois, Jean-Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sergio J Azevedo, Gisele Marinho, Joao Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, Andre Poisl Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuysse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, Jose Luis Leal, Francisco Francisco, Carolina Ibanez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Flechon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross-Goupil, Stephane Culine, Yohann Lorient, Gwenaelle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David Pfister, Carsten Ohlman, Michael Stoeckle, Manfred Wirth, Anja Lorch, Guenter Niegisch, Peter J Goebell, Martin Boegemann, Axel Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian Thomas, Thomas Hoefner, Andras Telekes, Judit Erzsebet Kosa, Janos Revesz,

Gyorgy Bodoky, Tibor Csozsi, Andras Csejtei, Lajos Geczi, Agnes Ruzsa, Zsuzsanna Kolonics, Jozsef Erfan, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger, Keren Rouvinov, David Sarid, Satoshi Fukasawa, Gaku Arai, Akito Yamaguchi, Akira Yokomizo, Tatsuya Takayama, Hidefumi Kinoshita, Eiji Kikuchi, Ryuichi Mizuno, Yasuhisa Fujii, Naoto Sassa, Yoshihisa Matsukawa, Kiyohide Fujimoto, Nobuaki Matsubara, Toshiki Tanikawa, Yoshihiko Tomita, Kazuo Nishimura, Masao Tsujihata, Masafumi Oyama, Naoya Masumori, Hiroomi Kanayama, Toshimi Takano, Yuji Miura, Jun Miyazaki, Akira Joraku, Tomokazu Kimura, Yoshiaki Yamamoto, Kazuki Kobayashi, Ronald De Wit, Maureen Aarts, Winald Gerritsen, Maartje Los, Laurens Beerepoot, Adel Izmailov, Sergey Igorevich Gorelov, Boris Yakovlevich Alekseev, Andrey Semenov, Vladimir Anatolyevich Kostorov, Sergey M Alekseev, Alexander Zyryanov, Vasilii Nikolaevich Oschepkov, Vladimir Aleksandrovich Shidin, Vladimir Ivanovich Vladimirov, Rustem Airatovich Gafanov, Petr Alexandrovich Karlov, David Brian Anderson, Lucinda Shepherd, Graham Lawrence Cohen, Bernardo Louis Rapoport, Paul Ruff, Nari Lee, Woo Kyun Bae, Hyo Jin Lee, Urbano Anido Herranz, Alejo Rodriguez-Vida, Rafael Morales Barrera, Enrique Grande, Teresa Alonso Gordo, Josep Guma Padro, Daniel Castellano Gauna, Jose Angel Arranz, Jose Munoz Langa, Regina Girones Sarrio, Alvaro Montesa Pino, Maria Jose Juan Fita, Yu-Li Su, Yung-Chang Lin, Wen-Pin Su, Ying-Chun Shen, Yen-Hwa Chang, Yi-Hsiu Huang, Virote Sriuranpong, Phichai Chansriwong, Vichien Srimuninnimit, Pongwut Danchaivijitr, Huseyin Abali, Sinan Yavuz, Ozgur Ozyilkan, Mehmet Ali Nahit Sendur, Meltem Ekenel, Mustafa Ozguroglu, Cagatay Arslan, Seyda Gunduz, Mustafa Ozdogan, Alison Birtle, Thomas Powles, Robert Huddart, Maria de Santis, Anjali Zarkar, Linda Evans, Syed Hussain, Christopher DiSimone, Antonio F Muina, Peter Schlegel, Haresh S Jhangiani, Michael Harrison, Dennis E Slater, David Wright, Ivor J Percent, Jianqing Lin, Clara Hwang, Ronac Mamtani, Sumati Gupta, Madhuri Bajaj, Robert Galamaga, John Eklund, James Wallace, Mikhail Shtivelband, Jason Jung-Gon Suh, Nafisa Burhani, Matthew Eadens, Krishna Gunturu, Earle Burgess, John Wong, Arvind Chaudhry, Peter Van Veldhuizen, **Stephanie Graff**, Christian A Thomas, Ian D Schnadig, Benedito Carneiro, Maha Hussain, Alicia Morgans, John T Fitzharris, Ira A Oliff, Jacqueline Vuky, Ralph Hauke, Ari Baron, Monika Joshi, Britt H Bolemon, Peter Jiang, Anthony E Mega, Maurice Markus, Nicklas Pfanzelter, William Eyre Lawler, Patrick Wayne Cobb, Jay G Courtright, Sharad Jain, Gurjyot Doshi, Vijay K Gunuganti, Oliver Alton Sartor, Scott W Cole, Hani Babiker, Edward M Uchio, Alexandra Drakaki, Heather D Manuel, Ajjai Alva, Elizabeth Guancial, Chunkit Fung, Anthony Charles, Robert J Amato, Yull Arriaga, Isaac Bowman, Steven Ades, Robert Dreicer, Evan Yu, David I Quinn, Mark Fleming,

11. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; **ASCENT Clinical Trial Investigators**. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N Engl J Med*. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206.

ASCENT Clinical Trial Investigators: Foluso Ademuyiwa, Philippe Aftimos, Anne Armstrong, Aditya Bardia, Frédéric Bigot, Adam Brufsky, Lourdes Calvo, Martínez, Lisa A Carey, Eva Ciruelos Gil, Alison Conlin, Javier Cortés, Florence Dalenc, Brooke Daniel, Michael Danso, Jorge Darcourt, Sami Diab, Jennifer Diamond, Véronique Diéras, Anne Favret, Mariía Fernáandez Abad, Cristiano Ferrario, Nelly Firmin, Christel Fontaine, Jean-

- Sebastien Frenel, Luca Gianni, **Stephanie Graff**, Erika Hamilton, Eric Harris, Lowell Hart, Susanna Hegewisch-, Becker Becker, Stéphanie Henry, Christie Hilton, Sara A Hurvitz, Sharad Jain, Kevin Kalinsky, Pinelopi Kechagioglou, Leonard Klein, Roberto Leon-Ferre, Florence Lerebours, Sibylle Loibl, Delphine Loirat, Rafael López, Filipa Lynce, Zulfiqar Malik, Laura Mansi, María Martínez García, Ingrid Mayer, Michael Meshad, Judith Meza-Junco, Rebecca Moroosse, Rita Nanda, Petros Nikolinakos, Joyce O'Shaughnessy, Mafalda Oliveira, Coral Omene, Felicity Paterson, Alejandra Perez, José Manuel Perez Garcia, Martine Piccart, Kevin Punie, Daniel Rayson, Sabela Recalde, Donald Richards, Paul Richards, Hope Rugo, Manuel Ruiz-Borrego, Mahasti Saghatchian, Sagar R Sardesai, Peter Schmid, Lowell Schnipper, Lee Schwartzberg, Priyanka Sharma, Amna Sheri, Saiqa Spensley, Christopher Stokoe, Jun Sun, Karen Tedesco, Sara M Tolaney, Tiffany Traina, Olivier Tredan, Michaela Tsai, Linda Vahdat, Tanya Wahl, Grace Wang, Robert Weaver, Rudolf Weide, Robyn Young, Amelia Zelnak
12. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordo T, Merchan JR, Winkquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; **CLEAR Trial Investigators**. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med*. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. PMID: 33616314.
- CLEAR Trial Investigators:** Robert Motzer, Toni Choueiri, Thomas Hutson, Luke Nordquist, Johanna Chock Bendell, Jamie Merchan, Saby George, Sandy Srinivas, Ulka N Vaishampayan, Elisabeth Heath, Brendan Curti, Andrew Pippas, Subramanya S Rao, Harry Drabkin, Theodore Gourdin, Mehmood H Hashmi, Jason Jung-Gon Suh, Nafisa D Burhani, Ana M Molina, Alan Koletsky, Robert S Alter, Carlos Alemany, Benjamin A Gartrell, Mike Cusnir, Harsha Vyas, Peter Van Veldhuizen, **Stephanie L Graff**, Ivor J Percent, Lucio Navarro Gordan, Vijay Manilal Patel, Christian Squillante, Mark Knapp, Daniel Spitz, Christopher Chay, Cameron Blair Harkness, Marc Matrana, Lindsay Carol Overton, Stephen L Richey, Donald A Richards, Habib M H Ghaddar, Sucharu Prakash, Ralph J Hauke, Manish Agrawal, Robert Galamaga, Ronald P Harris, Edward J Crane, David M Waterhouse, Samith T Kochuparambil, Anil Kapoor, Christina Canil, Eric Winkquist, Catherine Sperlich, George Bjarnason, Naveen Basappa, Wolfgang Christian Loidl, Horninger Wolfgang, Renate Pichler, Manuela Schmidinger, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolicka, Jiri Tomasek, Jana Prausova, Thomas Buchler, Petra Holeckova, Philippe Barthelemy, Diego Tosi, Luca Campedel, Aurelien Gobert, Sylvie Negrier, Stephane Oudard, Eric Voog, Sylvie Zanetta, Frédéric Rolland, Jens Bedke, Stefan Siemer, Jan Schleicher, Maria De Santis, Kurt Miller, Manfred Wirth, Lothar Bergmann, Michael Stahler, Philip Ivanyi, Viktor Gruenwald, Christoph Lutz, Jochen Heymanns, Martin Boegemann, Uwe Zimmerman, Gunhild von Amsberg, Sean R McDermott, Richard Bambury, Paul Donnellan, Oscar Breathnach, Raya Leibowitz-Amit, Avishay Sella, Olesya Goldman, Daniel Kejzman, Avivit Pe'er, David Sarid, Hovav Nechushtan, Raanan Berger, Victoria Neiman, Fabio Calabro, Paulo Pedrazzoli, Camillo Porta, Francesco Boccardo, Alketa Hamzaj, Ferdinando Riccardi, Ugo DeGiorgi, Sandro Pignata, Giovanni Lo Re, Francesco Massari, Daniele Santini, Vincenzo Emanuele Chiuri, Francesco Carrozza, Roberto Sabbatini, Giuseppe Procopio, Mimma Rizzo,

- Maria Suelmann, Alfonsus Eertwegh, Johannes van Thienen, Ewa Kalinka-Warzocha, Jacek Jassem, Violetta Sulzyc-Bielicka, Mandziuk Slawomir, Sergey A Tjulandin, Oleg Karyakin, Anna V Alyasova, Boris Ya Alekseev, Vsevolod Matveev, Alexander V Zyryanov, Evgeny I Kopyltsov, Vadim Kozlov, Jose Angel Arranz Arija, Pablo Borrega Garcia, Miguel Angel Climent Duran, Ignacio Duran Martinez, Begona Perez Valderrama, Emilio Esteban Gonzalez, Francisco Xavier Garcia Del Muro Solans, Jesus Garcia Donas, Teresa Alonso Gordo, Jose Pablo Maroto Rey, Begona Mellado, Maria Jose Mendez Vidal, Javier Puente Vazquez, Cristina Suarez Rodriguez, Enrique Grande Pulido, Guillermo Crespo Herrero, Julian Schardt, Jorg Beyer, Natalie Fischer, Hilary Glen, Loretta Sweeney, Jason Lester, Manon R Pillai, Robert E Hawkins, Thomas Powles, Jahangir M Malik, Christy Ralph, Sarah M Rudman, Thomas R Geldart, Aristotelis Bamias, Sofia Baka, Haralabos Kalofonos, Christos Papandreou, Vasilios Georgoulas, Konstantinos Papzisis, Choung-Soo Kim, Sun Young Rha, Seok Soo Byun, Seong I I Seo, Jin Soo Chung, Miso Kim, Bhumsuk Keam, Sung Hoo Hong, Jae Lyun Lee, Se Hoon Park, Tae Gyun Kwon, Ian Douglas Davis, Suet-Lai Shirley Wong, Ian John Byard, Andrew James Weickhardt, Howard Paul Gurney, Jeffrey Chee Hong Goh, Takahiro Osawa, Naoya Masumori, Takuya Koie, Shingo Hatakeyama, Mitsuru Saito, Yoshihiko Tomita, Toshimi Takano, Yuji Miura, Masayoshi Nagata, Go Kimura, Mototsugu Oya, Toshio Takagi, Takatsugu Okegawa, Keichi Kondo, Satoshi Fukasawa, Massfumi Oyama, Masatsugu Iwamura, Akira Komiya, Yoshihisa Matsukawa, Naoto Sassa, Satoshi Tamada, Masahiro Nozawa, Norihito Soga, Satoshi Anai, Kenichi Harada, Atsushi Takamoto, Jun Teishima, Hiroyuki Tsunemori, Masayuki Takahashi, Masatoshi Eto, Hideki Sakai, Takeshi Kishida, Osamu Ukimura
13. Huober J, Barrios CH, Niikura N, Jarzab M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H; **IMpassion050 Trial Investigators**. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. *J Clin Oncol*. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28. PMID: 35763704; PMCID: PMC9426828.
- IMpassion050 Trial Investigators**: L. Andrade, R.D. Freitas Junior, R. Hegg, J. Pedrini, S. Chia, L. Panasci, L. Provencher, G. Roldan Urgoiti; B. Melichar, M. Palacova; M. Braun, J. Huober, D. Langanke, M. Lux, M. Reinisch, C. Shem, J. Tio, M. Zaiss; M. Cazzaniga, P. Conte, M. De Laurentiis, S. De Placido, F. Montemurro, I. Paris, R. Pedersini, F. Puglisi, A. Santoro; M. Itoh, K. Kaneko, K. Matsumoto, S. Nakamura, N. Niikura, R. Nishimura, S. Ohsumi, M. Okada, A. Osaki, S. Saji, M. Takahashi, Y. Tanabe, T. Yamashita; H.K. Ahn, S-A. Im, K.H. Park, Y.H. Park; Z. Nowecki, I. Symonowicz, M. Jarzab, P. Wsocki; N. Falaleeva, I. Ganshina, P. Krivorotko, R. Safin, D. Stroyakovskii, L. Zhukova; J.L. Alonso, M.I. Blancas Lopez-Barajas, E. Ciruelos Gil, S. Escriva De Romani Muñoz, A. Gonzalez, F. Henao, B. Hernando Fernandez De Aranguiz, M. Margeli Vila, S. Morales Murillo, M. Muñoz Mateu, M. Ruiz Borrego, P. Sanchez Rovira; Y-C. Chang, S-C. Chen, C-F. Chung, H-C. Wang; **S. Graff**, E. Hamilton, M. Kwa.
14. **Graff SL**, Subbiah IM, Markham MJ, Matt-Amaral LB, Close JL, Griffith KA, Jagsi R. Frequency, Barriers, Outcomes, and Consequences of Reporting Sexual Harassment in Clinical Oncology. *JNCI Cancer Spectr*. 2023 Jan 3;7(1):pkac081. doi: 10.1093/jncics/pkac081. PMID: 36416149; PMCID: PMC9808769.
15. Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS,

- Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M; **monarchE Committee Members**. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. PMID: 36493792.
- monarchE Committee:** Jimenez MM, Johnston S, Boyle F, Steger GG, Neven P, Jiang Z, Campone M, Huober J, Shimizu C, Cicin I, Wardley A, Tolaney SM, Abuin GG, Zarba J, Lim E, Sant P, Liao N, Christiansen B, Eigeliene N, Martin-Babau J, Ettl J, Mavroudis D, Chiu J, Boer K, Nagarkar R, Paluck-Shimon S, Moscetti L, Sagara Y, Kim SB, Maciel MM, Tjan-Heijnen V, Broom R, Lacko A, Schenker M, Volkov N, Sim Yap Y, Coccia-Portugal M, Angel Garcia Saenz J, Andersson A, Chao TY, Gokmen E, Harputluoglu H, Berzoy O, Patt D, McArthur H, Chew H, Chalasani P, Kaufman P, Tedesco K, **Graff SL**.
16. **Graff SL**, Wildes T, Duma N, Dizon DS, LoConte NK, Mitchell E, Murphy MC, Perez EA, Temkin SM, Kunz PL, Winkfield KM. Understanding Modern Medical Centers: Beyond Simone-Intersectional Maxims for a New Era. *J Clin Oncol*. 2023 Mar 1;41(7):1350-1358. doi: 10.1200/JCO.22.01060. Epub 2022 Sep 27. PMID: 36166718.
 17. Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; **CAPitello-291 Study Group**. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med*. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. PMID: 37256976.
 - CAPitello-291 US Study Group:** Blau SH, **Graff S**, Mozayen M, Hamilton EP, Hart LL, Landry C, Sharma R, Sharma P, Thara E, Marathe OS, Irvin WJ, Daniel BR, Gudena V, Cao Y, Ademuyiwa FO, Coluzzi P, Rak-Tkaczuk KH, Neidhart J, Klein P, Mina L, Zhao Q, Teplinsky E, Rugo HS, O'Shaughnessy J, Sideras K, Giridhar KV
 18. Wang Y, Hacking SM, Li Z, **Graff SL**, Yang D, Tan L, Liu F, Zhang T, Zhao Z, Luo S, Du P, Jia S, Cheng L. Triple-negative Breast Carcinoma With Apocrine and Histiocytoid features: A Clinicopathologic and Molecular Study of 18 Cases. *Am J Surg Pathol*. 2023 Jun 13. doi: 10.1097/PAS.0000000000002073. Epub ahead of print. PMID: 37310016.
 19. **Graff SL**, Principe J, Galvin AM, Fenton MA, Strenger R, Salama L, Bansal R, Dizon DS, Begnoche MH. Evaluating Patient Experience in a Multidisciplinary Breast Cancer Clinic: A Prospective Study. *J Womens Health (Larchmt)*. 2024 Jan;33(1):39-44. doi: 10.1089/jwh.2022.0531. Epub 2023 Nov 23. PMID: 38011006.
 20. Majmudar S, **Graff SL***, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow. *J Med Internet Res*. 2023 Aug 21;25:e47784. doi: 10.2196/47784. PMID: 37603399; PMCID: PMC10477917. (*co-first author)
 21. Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluck-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A,

Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; **BRCA BCY Collaboration**. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA*. 2023 Dec 7:e2325463. doi: 10.1001/jama.2023.25463. Epub ahead of print. PMID: 38059899; PMCID: PMC10704340.

BRCA BCY Collaboration : de Azambuja, Evandro; Molinelli, Chiara; Paesmans, Marianne; Ameye, Lieveke; Amant, Frédéric; Brems, Hilde; Han, Sileny; Hatse, Sigrid; Nevelsteen, Ines; Neven, Patrick; Smeets, Ann; Van Rompuy, Chantal; Wildiers, Hans; Duhoux, Francois; Giugliano, Federica; Criscitiello, Carmen; Borea, Roberto; Arecco, Luca; Chirco, Alessandra; Bini, Federica; Venturelli, Marta; Cortesi, Laura; Ponzzone, Riccardo; Tomasi Cont, Nicoletta; Balmaña, Judith; Graffeo, Rossella; Luna Pais, Helena; Mohar, Alejandro; Palacios, Tamara; Da Ros, Lucia; Miolo, Gianmaria; Garutti, Mattia; Pastò, Brenno; Spazzapan, Simon; Viel, Alessandra; Pérez-Fidalgo, Alejandro; Colombo Bonadio, Renata; Peretz-Yablonski, Tamar; Anghelone, Chiara Annunziata Pasqualina; Della Valle, Angelica; Campanella, Maria; Guarneri, Valentina; Bas, Raphaelle; Heidelberg, Pierre-Etienne; Tredan, Olivier; de Talouet, Solenne; Bonadona, Valérie; Lasset, Christine; Acheritogaray, Marion; Senechal, Claire; Mariño, Monica; Córdoba, Octavi; Feldman, Didi; Pesce, Romina I.; Allemand, Carol; Riggi, Cecilia; Triarte, Maria Belen; Cortés Salgado, Alfonso; Cortes, Javier; Gion, María; Saavedra, Cristina; Rodriguez, Adela; Adamo, Barbara; Prat, Aleix; Hester, Anna; Duncckelmann, Sofia; Harbeck, Nadia; Marhold, Maximilian; Bartsch, Rupert; Mannsbarth, Constantin; Popovic, Lazar; Bozovic-Spasojevic, Ivana; Krivokuca, Ana; Dimitrijevic, Marija; Visani, Luca; Bettazzi, Beatrice; Livi, Lorenzo; Sposetti, Caterina; Sini, Valentina; Rognone, Alessia; Bianchini, Giampaolo; Patricelli, Maria Grazia; Rabaiotti, Emanuela; Gentilini, Oreste; Fontana, Andrea; Acconci, Giulia; Baldacci, Erica; Bianchini, Giulia; Pistelli, Mirco; Linn, Sabine; Kleiterp, Sieta; Moha, Daoud A.; NKI-AvL DataDesk Wetenschappelijke Administrative; Sarin, Rajiv; Sekar, Anberson; Atzori, Francesco; Loi, Francesco; Dessì, Mariele; O'Connor, Sarah; Nesci, Stephanie; James, Paul; Michael, Chris; Couch, Fergus J.; Olson, Janet E.; Larson, Nicole L.; Yadav, Siddhartha; Lopetegui, Nerea; Carey, Lisa A.; Abdou, Yara; Zagami, Paola; Di Rocco, Roberta; Baldassarri, Margherita; Bengala, Carmelo; Mariamidze, Elene; **Graff, Stephanie L.**; Haddad, Stephanie A.; Safran, Emma; Vasconcelos de Matos, Leonor; Ferreira, Arlindo; Negri, Serena; Dell'Oro, Cristina; Inzoli, Alessandra; Costa, Clarissa; Marchetta, Liliana; Lustberg, Maryam; Blansky, Deanna; Jeon, June; Ansari, Norin; Aguilar-y-Mendez, Dione ; Woodruff, Teresa K.; Swain, Monique; Miller, Madison; Leach, Richard; Fabi, Alessandra; Palazzo, Antonella; Paris, Ida; Kufel-Grabowska, Joanna; Synowiec, Agnieszka; Hancinova, Miriam; Tarbaj, Lukas; Sokolovic, Emir; Beslija, Semir; Ceric, Timur; Hasanbegović, Berisa; Foulkes, William D; Bianchi, Manuel A.; Tolosa, Pablo; Alvaro, Laura; Eriksson Bergman, Louise; Antone, Nicoleta; Damian, Cristina;

22. Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, **Graff SL**, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. *Ann Oncol*. 2023

Dec;34(12):1141-1151. doi: 10.1016/j.annonc.2023.09.3104. PMID: 38072514.

23. Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordo TA, Kozlov V, Alyasova A, Winqvist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; **CLEAR Trial Investigators**. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. *J Clin Oncol*. 2024 Jan 16;JCO2301569. doi: 10.1200/JCO.23.01569. Epub ahead of print. PMID: 38227898.

CLEAR Trial Investigators: Robert Motzer, Toni Choueiri, Thomas Hutson, Luke Nordquist, Johanna Chock Bendell, Jamie Merchan, Saby George, Sandy Srinivas, Ulka N Vaishampayan, Elisabeth Heath, Brendan Curti, Andrew Pippas, Subramanya S Rao, Harry Drabkin, Theodore Gourdin, Mehmood H Hashmi, Jason Jung-Gon Suh, Nafisa D Burhani, Ana M Molina, Alan Koletsky, Robert S Alter, Carlos Alemany, Benjamin A Gartrell, Mike Cusnir, Harsha Vyas, Peter Van Veldhuizen, **Stephanie L Graff**, Ivor J Percent, Lucio Navarro Gordan, Vijay Manilal Patel, Christian Squillante, Mark Knapp, Daniel Spitz, Christopher Chay, Cameron Blair Harkness, Marc Matrana, Lindsay Carol Overton, Stephen L Richey, Donald A Richards, Habib M H Ghaddar, Sucharu Prakash, Ralph J Hauke, Manish Agrawal, Robert Galamaga, Ronald P Harris, Edward J Crane, David M Waterhouse, Samith T Kochuparambil, Anil Kapoor, Christina Canil, Eric Winqvist, Catherine Sperlich, George Bjarnason, Naveen Basappa, Wolfgang Christian Loidl, Horninger Wolfgang, Renate Pichler, Manuela Schmidinger, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolicka, Jiri Tomasek, Jana Prausova, Thomas Buchler, Petra Holeckova, Philippe Barthelemy, Diego Tosi, Luca Campedel, Aurelien Gobert, Sylvie Negrier, Stephane Oudard, Eric Voog, Sylvie Zanetta, Frédéric Rolland, Jens Bedke, Stefan Siemer, Jan Schleicher, Maria De Santis, Kurt Miller, Manfred Wirth, Lothar Bergmann, Michael Stahler, Philip Ivanyi, Viktor Gruenwald, Christoph Lutz, Jochen Heymanns, Martin Boegemann, Uwe Zimmerman, Gunhild von Amsberg, Sean R McDermott, Richard Bambury, Paul Donnellan, Oscar Breathnach, Raya Leibowitz-Amit, Avishay Sella, Olesya Goldman, Daniel Kejzman, Avivit Pe'er, David Sarid, Hovav Nechushtan, Raanan Berger, Victoria Neiman, Fabio Calabro, Paulo Pedrazzoli, Camillo Porta, Francesco Boccardo, Alketa Hamzaj, Ferdinando Riccardi, Ugo DeGiorgi, Sandro Pignata, Giovanni Lo Re, Francesco Massari, Daniele Santini, Vincenzo Emanuele Chiuri, Francesco Carrozza, Roberto Sabbatini, Giuseppe Procopio, Mimma Rizzo, Maria Suelmann, Alfonsus Eertwegh, Johannes van Thienen, Ewa Kalinka-Warzocha, Jacek Jassem, Violetta Sulzyc-Bielicka, Mandziuk Slawomir, Sergey A Tjulandin, Oleg Karyakin, Anna V Alyasova, Boris Ya Alekseev, Vsevolod Matveev, Alexander V Zyryanov, Evgeny I Kopyltsov, Vadim Kozlov, Jose Angel Arranz Arija, Pablo Borrega Garcia, Miguel Angel Climent Duran, Ignacio Duran Martinez, Begona Perez Valderrama, Emilio Esteban Gonzalez, Francisco Xavier Garcia Del Muro Solans, Jesus Garcia Donas, Teresa Alonso Gordo, Jose Pablo Maroto Rey, Begona Mellado, Maria Jose Mendez Vidal, Javier Puente Vazquez, Cristina Suarez Rodriguez, Enrique Grande Pulido, Guillermo Crespo Herrero, Julian Schardt, Jorg Beyer, Natalie Fischer, Hilary Glen, Loretta Sweeney, Jason Lester, Manon R Pillai, Robert E Hawkins, Thomas Powles, Jahangir M Malik, Christy Ralph, Sarah M Rudman, Thomas R

- Geldart, Aristotelis Bamias, Sofia Baka, Haralabos Kalofonos, Christos Papandreou, Vasilios Georgoulis, Konstantinos Pappazisis, Choung-Soo Kim, Sun Young Rha, Seok Soo Byun, Seong I I Seo, Jin Soo Chung, Miso Kim, Bhumsuk Keam, Sung Hoo Hong, Jae Lyun Lee, Se Hoon Park, Tae Gyun Kwon, Ian Douglas Davis, Suet-Lai Shirley Wong, Ian John Byard, Andrew James Weickhardt, Howard Paul Gurney, Jeffrey Chee Hong Goh, Takahiro Osawa, Naoya Masumori, Takuya Koie, Shingo Hatakeyama, Mitsuru Saito, Yoshihiko Tomita, Toshimi Takano, Yuji Miura, Masayoshi Nagata, Go Kimura, Mototsugu Oya, Toshio Takagi, Takatsugu Okegawa, Keichi Kondo, Satoshi Fukasawa, Massfumi Oyama, Masatsugu Iwamura, Akira Komiya, Yoshihisa Matsukawa, Naoto Sassa, Satoshi Tamada, Masahiro Nozawa, Norihito Soga, Satoshi Anai, Kenichi Harada, Atsushi Takamoto, Jun Teishima, Hiroyuki Tsunemori, Masayuki Takahashi, Masatoshi Eto, Hideki Sakai, Takeshi Kishida, Osamu Ukimura
24. Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DS, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers. *Nat Cancer*. 2024 Mar 25. doi: 10.1038/s43018-024-00752-x. Epub ahead of print. PMID: 38528112.
 25. Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, **Graff SL**, Antonarakis ES, Goel S, Sledge G, Lopes G. The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors. *Cancers (Basel)*. 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. PMID: 38672653; PMCID: PMC11049662.
 26. Kim KW, Lopresti M, **Graff SL**, Strenger R, Hsu E, Witherby S, Dizon DS, Fenton MA. Fulfilling the role of a parent while undergoing treatment for cancer: a review of the literature and the potential impact of childcare support on cancer outcomes. *American Journal of Clinical Oncology* ();10.1097/COC.0000000000001102, April 23, 2024. | DOI: 10.1097/COC.0000000000001102
 27. Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, Jacene H, Rubio IT, Schoones JW, Peeters MV, Poortmans P, Mann RM, **Graff SL**, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). *Eur J Nucl Med Mol Imaging*. 2024 May 14. doi: 10.1007/s00259-024-06696-9. Epub ahead of print. PMID: 38740576.
 28. Freedman RA, Caswell-Jin JL, Hassett M, Somerfield MR, Giordano SH; **and Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel**. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. *J Clin Oncol*. 2024 May 20;JCO2400886. doi: 10.1200/JCO.24.00886. Epub ahead of print. PMID: 38768407.
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel: Mariana Chavez-MacGregor, Amy H Comander, Zoneddy Dayao, Andrea Eisen, Rachel A Freedman, Ragisha Gopalakrishnan, **Stephanie L Graff**, Michael J Hassett, Tari A King, Gary H Lyman, Gillian Rice Maupin, Cheryl L Perkins, Melinda L Telli, Maureen E Trudeau, Antonio C Wolff, Sharon H Giordano

OTHER PEER-REVIEWED PUBLICATIONS

29. **Schutt, SL.** The Puppet Show. *Missouri Medicine*. April 2001: 98(144-5)
30. Cook JW, Dillmon M, **Graff SL**, Pentz RD, Srivastava R, Close JL. Caring for Colleagues and Loved Ones With Cancer. *Am Soc Clin Oncol Educ Book*. 2018 May 23;38:903-908. doi: 10.1200/EDBK_201451. PMID: 30231376.
31. **Graff, SL.** Perspective: Cost Barriers and Beyond. *Oncology (Williston Park)* 33 (2): 54-7 Feb 2019
32. **Graff SL.** The Cattle Don't Care. *J Clin Oncol*. 2019 May 1;37(13):1136-1138. doi: 10.1200/JCO.19.00255. Epub 2019 Mar 18. PMID: 30883247.
33. LaCasce A, **Graff SL**, Gao J, Close J, Boulmay B. Preparing Fellows for Graduation: Perspectives on Career Guidance. *Am Soc Clin Oncol Educ Book*. 2019 Jan;39:609-614. doi: 10.1200/EDBK_242603. Epub 2019 May 17. PMID: 31099656.
34. Ersek JL, **Graff SL**, Arena FP, Denduluri N, Kim ES. Critical Aspects of a Sustainable Clinical Research Program in the Community-Based Oncology Practice. *Am Soc Clin Oncol Educ Book*. 2019 Jan;39:176-184. doi: 10.1200/EDBK_238485. Epub 2019 May 17. PMID: 31099620.
35. **Graff SL.** Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy. *JCO Oncol Pract*. 2021 Nov 15:OP2100720. doi: 10.1200/OP.21.00720. Epub ahead of print. PMID: 34780307.
36. Anampa-Guzmán A, Freeman-Daily J, Fisch M, Lou E, Pennell NA, Painter CA, Sparacio D, Lewis MA, Karmo M, Anderson PF, **Graff SL**; Collaboration for Outcomes using Social Media in Oncology. The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator. *JCO Oncol Pract*. 2022 Aug;18(8):578-583. doi: 10.1200/OP.21.00763. Epub 2022 Mar 28. PMID: 35344398; PMCID: PMC9377686.
37. Chidharla A, Utengen A, Attai DJ, Drake EK, van Londen GJ, Subbiah IM, Henry E, Murphy M, Barry MM, Manochakian R, Moerdler S, Loeb S, **Graff SL**, Leyfman Y, Thompson MA, Markham MJ. Social Media and Professional Development for Oncology Professionals. *JCO Oncol Pract*. 2022 Aug;18(8):566-571. doi: 10.1200/OP.21.00761. Epub 2022 Mar 21. PMID: 35312343; PMCID: PMC9377722.
38. **Graff SL.** People Like Us. *J Clin Oncol*. 2023 Feb 1;41(4):931-932. doi: 10.1200/JCO.22.01835. Epub 2022 Nov 8. PMID: 36346963.
39. Sagaityte E, Dowd RS, Lane K, **Graff SL**, Toms SA. The Role of RNA Epitranscriptomics and the RNA Fat Mass and Obesity-Associated Demethylase in Triple Negative Breast Cancer. *Advances in Breast Cancer Research*, 2023: 12, 27-50. doi: 10.4236/abcr.2023.122004.
40. Vaz SC, **Graff SL**, Ferreira AR, Debiassi M, de Geus-Oei L-F. PET/CT in Patients with Breast Cancer Treated with Immunotherapy. *Cancers (Basel)*. 2023 May 5;15(9):2620. doi: 10.3390/cancers15092620. PMID: 37174086; PMCID: PMC10177398.
41. **Graff SL**, Yang F, Abdou Y. Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer. *Clin Breast Cancer*. 2023 May 13:S1526-8209(23)00108-8. doi: 10.1016/j.clbc.2023.05.003. Epub ahead of print. PMID: 37407378.
42. Prioritization of Antineoplastic Agents in Limited Supply, American Society of Clinical Oncology Clinical Guidance Statement, **ASCO Drug Shortages Task Force**. Published online May 22, 2023 <https://old-prod.asco.org/practice-patients/practice-support/drug-shortages/clinical-guidance>

ASCO Drug Shortages Task Force: Aparicio A, Campbell T, Castiel M, Colevas D, Diaz M, Eng C, **Graff SL**, Gregg X, Hoffman-Censits J, James S, Briseno Kenney L, Klix M, Lee N, Markham MJ, McKenzie N, Pant S, Persing B, Rugo H, Saeed A, Santos E, Scalici J, Shroff R, Symington B, Tagawa S, Teplinsky E, Traina T, Ulahannan S, Wilfong L, Winegarden JD, Zarwan C

Breast Cancer Guidance, Prioritization of Antineoplastic Agents in Limited Supply, American Society of Clinical Oncology Clinical Guidance Statement, ASCO Drug Shortages Breast Cancer Task Force. Published online June 12, 2023 at <https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/practice-patients/documents/2023-ds-breast-recs.pdf>

ASCO Breast Cancer Drug Shortages Task Force: Deboer R, Zarwan C, Rugo H, **Graff SL**, Park K, Nahleh Z, Telli M, Kaufmann T, Nackos E, Thompson A, Robson ME, Ruddy KJ, Wright J, Allison K, Anders C, Cortes J, Puztai L, Spears P, Gralow J, Traina T, Geisel R, MacGregor Chavez M

43. Haddad S, Dizon DS, Graff SL. Sequencing Systemic Therapy in Hormone-Receptor Positive Metastatic Breast Cancer: A Modern Paradigm. *J Chinese Clinical Oncology*, 2023. Published online Aug 10, 2023. doi: 10.21037/cco-23 <https://cco.amegroups.org/article/view/116368>
44. Fenton MA, Tarantino P, **Graff SL**. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. *Curr. Oncol.* 2023, 30(12), 10211-10223; <https://doi.org/10.3390/curroncol30120743>
45. Ali A, **Graff SL**. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan. *Curr Oncol Rep.* 2023 Dec 13. doi: 10.1007/s11912-023-01478-2. Epub ahead of print. PMID: 38091201
46. Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM, Poortmans P, Cardoso F, Jacene H, **Graff SL**, Rubio IT, Peeters MV, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines. *Eur J Nucl Med Mol Imaging.* 2024 May 2. doi: 10.1007/s00259-024-06694-x. Epub ahead of print. PMID: 38693453.

BOOKS AND BOOK CHAPTERS

47. Stages of IB to IIIA non-small cell lung cancer: the case for induction versus adjuvant chemotherapy, Multidisciplinary Approach to Lung Cancer. **Graff SL**, Kelly K. Demos Medical Publishing, 2011
48. Dr. Susan Love's Breast Book, 7th Edition. Love SM, Love E. with contributing authors **Graff SL**, Green L. Hancette Go. November 7, 2023. ISBN-10: 0306833255, ISBN-13: 978-0306833250
49. Breast Cancer, Chapter 11. Graves T, **Graff SL**, Hepel J, Fenton MA, Chudasama R, Dizon DS. The Principles and Practice of Gynecologic Oncology, 8th Edition. Chi D, Khabele D, Dizon DS, Yashar CM. Wolters Kluwer Health, Inc. Published May 31, 2024. ISBN/ISSN: 9781975183271

MULTICENTER TRIALS

50. Phase I/II study of the combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma (NCT01496118) Site Sub-Investigator
 - Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. *Haematologica.* 2015

- May;100(5):670-6. doi: 10.3324/haematol.2014.119735. Epub 2015 Feb 20. PMID: 25710456; PMCID: PMC4420216.
51. GC-627-02: A Phase II, Randomized, Multi-Center, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. (NCT03252431; Generon) Principal Investigator
 - Glaspy J, Tang T, Ruddy D, Yan X, Bondarenko I, Krasnozhan D; A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. *Blood* 2014;124(21):1584. doi: <https://doi.org/10.1182/blood.V124.21.1584.1584>
 52. A Randomized, Double-Blind, Multi-center, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin. Site Sub-Investigator
 - Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. *Neuroendocrinology*. 2015;102(1-2):18-25. doi: 10.1159/000381715. Epub 2015 Mar 21. PMID: 25824001.
 53. A Randomized, Open-Label Phase 3 Study of MM-398 versus 5-Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer. (Merrimack Pharmaceuticals; NCT01494506) Sub-Investigator
 - Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartzmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet*. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29.
 54. A Phase II Study of the Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor (GIST). Site Sub-Investigator
 - Bendell JC, Bauer TM, Lamar R, Joseph M, Penley W, Thompson DS, Spigel DR, Owers R, Lane CM, Earwood C, Burris HA 3rd. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors. *Cancer Invest*. 2016 Jul 2;34(6):265-70. doi: 10.1080/07357907.2016.1193746. Epub 2016 Jul 5. PMID: 27379708.
 55. A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer (BRE 274, Innocrine Pharmaceuticals; NCT02580448), Principal Investigator.
 - Gucalp A, Danso MA, Elias AD, Bardia A, Ali HY, Potter D, Gabrail NY, Haley BB, Khong HT, Riley EC, Ervin L, Eisner JR, Baskin-Bey E, Moore ER, and Traina TA; Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01. *Journal of Clinical Oncology* 2017 35:15_suppl, 1102
 56. A Phase III, randomized, double-blind placebo-controlled study of BKM120 with

- fulvestrant, in postmenopausal women with hormone receptor-positive HER-2 negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment. (BELLE2 NCT01610284), Site Principal Investigator
- Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30
57. A Multinational, Multicenter, Randomized, Phase 3 Study of Tese taxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane, (BRE 303) Site Principal Investigator
- O'Shaughnessy J, Piccart M, Schwartzberg LS, Cortes J, Harbeck N, Seock-Ah I, Rugo HS, Untch M, Yardley DA, Bondarenko I, Chan S, Dieras V, Pegram MD, Kroll S, O'Connell JP, Wei T, Tang K, Seidman AD. CONTESSA: A multinational, multicenter, randomized, phase III registration study of tese taxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. *Journal of Clinical Oncology* 2019 37:15_suppl, TPS1107-TPS1107
58. Phase IIA Study of Transtuzumab/pertuzumab, erlotibin, vemurafenib and Vismodegib in advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents (NCT02091141), Site Principal Investigator
- Hainsworth JD, Meric-Bernstam F, Swanton C, Hurvitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIA Multiple Basket Study. *J Clin Oncol.* 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10. Erratum in: *J Clin Oncol.* 2019 Feb 1;37(4):360. PMID: 29320312.
59. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER-2 Negative Breast Cancer. (BRE-197, NCT 01527487). Site Principal Investigator
- Yardley DA, Shipley D, Zubkus J, Wright GL, Ward PJ, Mani A, Shastry M, Finney L, DeBusk L, Hainsworth JD. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer. *Clin Breast Cancer.* 2019 Feb;19(1):1-9. doi: 10.1016/j.clbc.2018.08.006. Epub 2018 Aug 23. PMID: 30245148.
60. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once Every 3-Weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-cycle Chemotherapy. Site Sub-Investigator
- Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety

- and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC. *J Thorac Oncol*. 2020 Feb;15(2):190-202. doi: 10.1016/j.jtho.2019.10.005. Epub 2019 Oct 16. PMID: 31629060.
61. A multi-center, randomized, double blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int 1risk) and transfusional iron overload (TELESTO, NCT00940602) Site Sub-Investigator
 - Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. *Ann Intern Med*. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24. PMID: 32203980.
 62. A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline-based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple Negative Breast Cancer (BRE 293, ImPassion031, NCT03197935) Site Principal Investigator
 - Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *Lancet*. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20. PMID: 32966830.
 63. The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection (NCT03085888), Site Sub-Investigator
 - Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann Oncol*. 2020 Jun;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011. Epub 2020 Mar 30. PMID: 33506766; PMCID: PMC8274402.
 64. A multicenter, double-blind, placebo-controlled, randomized phase III trial to compare efficacy and safety of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease (NCT03659136), Site Principal Investigator
 - Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. *Breast Cancer Res*. 2021 Jan 15;23(1):8. doi: 10.1186/s13058-020-01382-8. PMID: 33451345; PMCID: PMC7811234.
 65. A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (METRIC, Celldex, BRE-231, NCT01997333) Site Principal Investigator
 - Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J, Montero AJ, Ma C, Nanda R, Wright GS, He Y, Hawthorne T, Bagley RG,

- Halim AB, Turner CD, Yardley DA. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. *NPJ Breast Cancer*. 2021 May 20;7(1):57. doi: 10.1038/s41523-021-00244-6. PMID: 34016993; PMCID: PMC8137923.
66. Phase I-II trial of H3B-6545, an antagonist of estrogen receptor alpha, in locally advanced/metastatic ER +, HER2 - breast cancer (BRE 287, H3 Biomedicine, NCT03250676), Site Principal Investigator
- Hamilton EP, Wang JS, Pluard TJ, Johnston SRD, Morikawa A, Dees EC, Jones RH, Haley BB, Armstrong AC, Cohen AL, Munster PN, Wright GLS, Kayali F, Korpall Manav, Xiao JA, Long J, Destenaves B, Gao L, Gualberto A, Juric D, Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. *J Clin Oncol* 39, no. 15_suppl (May 20, 2021) 1018-1018
 - Hamilton EP, Wang JS, Pluard TJ, Johnston SRD, Morikawa A, Dees EC, Jones RH, Haley BB, Armstrong AC, Cohen AL, Munster PN, Wright GLS, Kayali F, Korpall, Yu L, Cantagallo L, Destenaves B, Zhang Z, Gao L, Pipas MJ, Sahmouud T, Gualberto A, Juric D, Abstract PD8-06: Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. *Cancer Res* 15 February 2021; 81 (4_Supplement): PD8-06. <https://doi.org/10.1158/1538-7445.SABCS20-PD8-06> (Poster Spotlight Session, San Antonio Breast Cancer Symposium 2021)
67. A National Phase IIIb, Multi-center, Open Label Study for Women and Men With Hormone-receptor Positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Ribociclib (LEE011) in Combination With Letrozole (RIBECCA, Novartis, NCT03096847), Principal Investigator
- Mattea Reinisch, Arndt Nusch, Thomas Decker, Andreas Hartkopf, Bernhard J Heinrich, Christian M Kurbacher, Roswitha Fuchs, Hans Tesch, Petra Krabisch, Sara Y Brucker, Tanja Fehm, Wolfgang Janni, Sherko Kuemmel, Diana Lüftner, Andreas Schneeweiss, Martin Schuler, Claudia Voges, Joerg Schubert, Peter A Fasching; Abstract PS10-31: Ribbecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results. *Cancer Res* 15 February 2021; 81 (4_Supplement): PS10-31. <https://doi.org/10.1158/1538-7445.SABCS20-PS10-31>
 - Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Gjerga E, Hennig S, Schaper S, Na IK, Keller U, Brucker S, Decker T, Fasching P, Fehm T, Janni W, Kümmel S, Schneeweiss A, Schuler M, Lüftner D, Busse A. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. *Eur J Cancer*. 2022 Feb;162:45-55. doi: 10.1016/j.ejca.2021.11.025. Epub 2021 Dec 23. PMID: 34953442.
68. TRINITY-1: A Phase I/II, single arm, open-label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with ER+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor: Triplet with Ribociclib, AfINitor® and AI posT CDK 4/6 Inhibitor (Novartis, BRE-279, NCT 02732119), Site Principal Investigator

- Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha DS, Moulder S; Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITY-1). *Clin Cancer Res* 1 August 2021; 27 (15): 4177–4185.
69. The impact of HER2 heterogeneity on the treatment of early-stage HER2-positive breast cancer: a phase II study of T-DM1 in combination with Pertuzumab in the preoperative setting. (BRE 263, NCT02326974), Principal Investigator
- Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. *Cancer Discov.* 2021 Oct;11(10):2474-2487. doi: 10.1158/2159-8290.CD-20-1557. Epub 2021 May 3. PMID: 33941592; PMCID: PMC8598376.
70. A Phase Ib, Open-Label, Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with: Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Doxorubicin with Cyclophosphamide in HER2-Negative Breast Cancer (BRE261, NCT02605915), Site Principal Investigator.
- Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. *Clin Breast Cancer.* 2021 Dec;21(6):539-551. doi: 10.1016/j.clbc.2021.04.011. Epub 2021 May 15. PMID: 34154926.
71. A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast02, NCT03523585), Site Principal Investigator
- André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Royslance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. *Lancet.* 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. PMID: 37086745.
72. A phase III, trial of ribociclib w/endocrine therapy as an adjuvant treatment in HR +, HER2-early breast cancer (NCT03701334, NATALEE, BRE 322, Novartis), Site Principal Investigator
- Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia A, Im SA, Ruiz-Borrego M, Loi A, Xu B, Hurvitz S, Barrios B, Untch M, Moroosse R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A,

- Taran T, Hortobagyi G; Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. *N Engl J Med* 2024; 390:1080-1091 DOI: 10.1056/NEJMoa2305488
73. A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL; NCT04109066; BRE 345, Bristol-Myers Squibb), Site Principal Investigator
 - Loi S, Curigliano G, Salgado RF, et al. A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2- primary breast cancer (BC). Presented at ESMO Congress 2023. Oct. 20-24, 2023. Madrid, Spain. Abstract LBA20.
 74. Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02; NCT03975647; BRE 343; Seattle Genetics), Site Principal Investigator
 - Hurvitz, Sara. GS01-10 HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer. Presented at San Antonio Breast Cancer Symposium 2023 General Session 1 (GS01-10)
 75. A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications (NCT04024436, FOENIX-MBC2, BRE336, Taiho), Site Principal Investigator
 - Jhaveri K, Hutchinson K, Im SA, Juric D, Kalinsky K, Lei G, Loi S, Loibyl S, Saura C, Schutzman S, Shankar N, Song C, Stout T, Thanopoulou, Turner N. GS03-13 Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis. Presented San Antonio Breast Cancer Symposium 2023 General Session 3
 76. A Randomized, Multicenter, Open-Label, Two-Arm Phase II Neoadjuvant Study Evaluating the Efficacy, Safety and Pharmacokinetics of GDC-9545 plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with Estrogen-Receptor Positive and Her2 Negative untreated Early Breast Cancer (BRE 357, NCT04436744; Hoffman-Roche), Principal Investigator
 - Peter A. Fasching et al. Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.. *JCO* 40, 589-589(2022). DOI:10.1200/JCO.2022.40.16_suppl.589
 77. Randomized Phase III Trial Evaluating The Role of Weight Loss In Adjuvant Treatment Of Overweight And Obese Woman With Early Breast Cancer (Alliance: A011401, BWEL Study; NCT02750826) Site Sub- Investigator
 - Jennifer A. Ligibel et al. Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.. *JCO* 41, 12001-12001(2023). DOI:10.1200/JCO.2023.41.16_suppl.12001

PUBLICATIONS IN SUBMISSION

1. Strandberg J, Louie A, Lee S, Hahn M, Srinivasan P, George A, De La Cruz A, Zhang L, Hernandez Borrero L, Huntington K, De La Cruz P, Seyhan AA, Koffer PP, Wazer DE, DiPetrillo PA, Azzoli CJ, Rounds SI, **Graff SL**, Abbas AE, Zhou L, El-Deiry WS. TRAIL agonists rescue mice from radiation-induced lung injury. *In Submission*. Preprint available online: bioRxiv 2023.06.12.544681; doi: <https://doi.org/10.1101/2023.06.12.544681>
2. **Graff SL**. “There’s Never a Good Time: Navigating Graduate Medical Education while Pregnant” Parenting While PhDing: Surviving and Improving the Working Conditions of Graduate Student Parents, edited by Jenna Morton-Aiken and Jackie Hoermann-Elliott. *In Submission*.
3. Louie AD, Bansal R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR, Chalasani P, El-Deiry WS, Dizon DS, **Graff SL**. Genomic characterization of breast cancer by metastatic site and variable co-expression of genomic mutations on survival: the impact of CDH1 and PIK3CA. *In submission*.
4. **Graff SL**, Freeman E, Roach M, Wilson W, Cagle C, Lunsford S, Maravic MC, Farley R, Gullatte M, Stemland J, Wochal P, Katz J, Hoffner B, Scott JM, May SG. Patient-centered collaborative research: Investigating the salience of clinical meaningfulness and clinically meaningful outcomes in metastatic breast cancer care delivery. *In submission*.
5. Association of androgen receptor expression with tumor immune landscape and treatment outcomes of patients with breast cancer. Jayachandran P, Deshmukh SK, Wu S, Ribeiro JR, Kang I, Xiu J, Farrell A, Battaglin F, Spicer D, Soni S, Zhang W, Ashouri K, Millstein J, Ma CX, **Graff SL**, Radovich M, Sledge GW, Lenz HJ, Torres ER. *In submission*.

ABSTRACTS

Includes abstracts not otherwise published or presented as part of other ongoing work; published projects have been removed

1. Huang, CH, **Graff SL**, Madan R, Kelly K., Insulin Growth Factors Receptor – 1 Expression in Small Cell Lung Cancer. *J Clin Oncol* 2010; 28(15S):e21098.
2. **Graff SL**, Wisner P, Shay-Zapien G, Logan M, Moorman D. The value of breast cancer survivorship care plans: Results from a community survey. American Society of Clinical Oncology Annual meeting, Abstract #e22125, June 2018.
3. Prochaska, LH, Godwin AK, Kimler BF, **Graff SL**, et al. Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer. San Antonio Breast Cancer Symposium, December 2016. Abstract P5-16-02.
4. Hamilton EP, Petit T, Pistilli B, Goncalves A, Ferreira AA, Dalenc F, Cardoso F, Mita MM, Dezentjé VO, Manso LM, **Graff SL**, Bidard FC, Aftimos PG, Escrivá S, Afonso N, Wasserman E, Bol K, Stalbovskaia V, Vliet A, Bachelo T. Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. *J Clin Oncol* 38: 2020 (suppl; abstr 3093)
5. Louie AD, Chudasama R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR, Chalasani P, Obeid E, El-Deiry WS, Dizon D, **Graff SL**. Mutational landscape and immune infiltration of breast cancer metastases to gynecologic and other organs, Abstract 451, Spotlight Poster-Discussion Session 6: Genomic and Genetic Analysis on Metastases. 2021 San Antonio Breast Cancer Symposium

6. Kalinsky K, Layman RM, Kaufman PA, **Graff SL**, Bianchini G, Martin M, Zhou Y, Knoderer, Litchfield LM, Wander SA. postMONARCH: A phase 3 study of abemaciclib plus fulvestrant vs placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy, American Society of Clinical Oncology Annual Meeting 2022, Poster Presentation, Clinical Trials in Progress
7. El-Deiry WS, Arnoff T, Sahin I, Khatri I, Lou E, Liu SV, Borghaei H, Plimack E, Subbiah V, Khan H, Carneiro B, Safran H, **Graff SL**, Dizon DS, Heath E, Wong E, George A, Hahn M, Chang WI, Raugi A, DeSousa A, Abbas A, Azzoli C, Demeure M, Marshall J, Lenz HJ, Doebele RC, Abraham J, Kurzrock R, Xiu J. A Pancancer analysis of impact of MDM2/MDM4 (MDMX) on immune checkpoint blockade (ICB). ASCO Annual Meeting 2022, Poster Presentation, Developmental Therapeutics—Immunotherapy June 5, 2022, #2630
8. Bustos MA, Yin J, Brodskiy P, Kang I, **Graff SL**, Sammons S, Dawar R, Spetzler D, Hoon DSB; Association of Interleukin-enhanced factor 2 (ILF2) expression with prognosis and clinico-genomic features in breast cancer (BC) patients with BRCA1/2 mutations. ASCO Annual Meeting 2022, Poster Presentation in Breast Cancer- Metastatic, Monday, June 6, 2022, #1030
9. O’Shaughnessy J, Yardley D, Hart L, Bardia A, Razavi P, **Graff SL**, Wogen J, McDermott C, Dionne PA, Haftchenary S, Pathak S, Tolaney S. (P3-03-12) Risk of recurrence with adjuvant endocrine therapy in real world patients with hormone receptor positive/human epidermal growth factor receptor-negative early breast cancer: a US database analysis. San Antonio Breast Cancer Symposium 2022, Epidemiology, Risk, and Prevention PS-03-12, December 7, 2022
10. Hensing WL, Xiu J, **Graff SL**, Kang I, Torres ER, Heeke AL, Davis A, Bagegni N, Clifton K, Bose R, Ma C, Ademuyiwa FO. Prevalence and Prognosis of ER-loss in advanced invasive lobular carcinomas. San Antonio Breast Cancer Symposium, Prognostic and Predictive Factors, P3-05-08. December 7, 2022.
11. Bansal R, McGrath J, Bustos M, Rodriguez E, Sammons SL, Accordino ML, Meisel J, Gatti-Mays M, **Graff SL**. Mutational Landscape of HER2-Low Breast Cancer. San Antonio Breast Cancer Symposium, 2022. Poster Presentation, Her2Low Special Session, HER2-12, Thursday December 8, 2022 5:00-6:15 PM
12. Louie AD, Chudasama R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR, Chalasani P, Obeid E, El-Deiry WS, Dizon D, **Graff SL**. Genomic characterization of breast cancer metastases reveals differences in rates of PIK3CA mutation across metastatic sites and worse survival in patients with concurrent CDH1 mutation treated with PI3K inhibitor. Society of Surgical Oncology Annual Meeting, March 2023. *Accepted for Oral Presentation*.
13. **Graff SL** Bansal R, Adeyelu T, Elliott , Walker A, Bustos M, Rodriguez E, Accordino ML, Meisel J, Gatti-Mays M, Hsu E, Kaklamani V, Oberley M, Sledge G, Sammons SL. Impact of Her2 Low on Survival in Patients Treated with Standard Therapies in Advanced Breast Cancer. Poster Presentation, European Society of Clinical Oncology: Breast Congress 2023.
14. El-Deiry WS, **Graff SL**, Azzoli CG, Dizon DS, Fenton MA, Sikov WM, Safran HP, Khan H, Khurshid H, Schumacher A, Zhou L, Zhao S, Seyhan AA, Roxanne Wood R, Winer AA, Monden A, Calleja EM, Ross EA. BrUOG 387: Phase Ib investigator-initiated trial of an HSP90i combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb) deficiency (IND163592; NCT05655598). Poster Presentation, Clinical Trials in Progress, American Society of Clinical Oncology Annual

Meeting 2023

15. **Graff SL**, Tolaney S, Hart L, Razavi P, Fasching PA, Janni W, Schwartzberg L, Lanoue B, Pathak P, Salas TR, Khakwani A, McDermott C, O’Shaughnessy J. Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) early breast cancer (EBC): a US database analysis. Poster: Breast Cancer—Local/Regional/Adjuvant, American Society of Clinical Oncology Annual Meeting 2023
16. Jayachandran P, Deshmukh SK, Wu S, Enriquez K, Irene Kang I, Xiu J, Farrell A, Battaglin F, Mittal P, Lu J, Soni S, Zhang W, Millstein J, Ma CX, **Graff SL**, Radovich M, Lenz H, Spicer D, Sledge G, Torres ER. Comprehensive Characterization of Androgen Receptor Expression in Breast Cancer, Poster: Breast Cancer—Metastatic, American Society of Clinical Oncology Annual Meeting 2023
17. **Graff SL**, Freeman E, Roach M, Wilson W, Stemland J, Chan B, Wochal P, Katz J, May SG. “Forging a Patient-Centered Collaborative Research Path: Unveiling Perspectives on Clinical Meaningfulness in Metastatic Breast Cancer with Clinicians, Patients, and Caregivers” *Poster Presentation*, American Society of Clinical Oncology Quality Care Symposium 2023.
18. **Graff SL**, Elliott A, Mahtani RL, Tan AR, Nabhan C, Holder SL, An Analysis of Proviral Insertion Site of Moloney Murine Leukemia Virus 1 Kinase Expression (PIM1) and Clinical Outcomes in Advanced Breast Cancer (ABC). *Poster Presentation*, European Society of Medical Oncology Congress 2023
19. **Graff SL**, Freeman E, Roach M, Wilson R, Fairley R, Guallatte M, Stemland J, Chan B, Wochal P, Katz J, May-Slater S. Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making: Experiences and Perspectives of Patients, Caregivers, and Clinicians. 2023 San Antonio Breast Cancer Symposium. *Poster Presentation*.
20. Haddad, SA, **Graff SL**, Wang Y, Taneja C, Leonard K, Fenton MA. Safety and Efficacy of KEYNOTE-522 in combination with anti-retroviral therapy in a patient with HIV and triple-negative breast cancer. Clinical Case Studies, 2023 San Antonio Breast Cancer Symposium 2023. *Poster Presentation*
21. Bansal R, Adeyelu T, Elliott A, Tan A, Meisel J, Oberley M, **Graff SL**, Reis-Filho JS, Sledge G, Sammons S, Rosenberger LH. Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy. San Antonio Breast Cancer Symposium 2023. *Poster Presentation*
22. Loi S, Johnston S, Arteaga C, **Graff SL (presenting author)**, Chandarlapaty S, Goetz MP, Desmedt C, Reis-Filho JS, Sasano H, Rodrik-Outmezguine V, Sireci A, Sandoval C, Won H, Liu D, Litchfield LM, Turner N. “Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer” *accepted for Poster Spotlight Discussion*, “Prognostic and predictive uses of cell free DNA,” Wednesday, December 6, 2023, San Antonio Breast Cancer Symposium 2023
23. Turner N, Reis-Filho JS, Goetz MP, Desmedt C, Chandarlapaty S, Sasano H, Arteaga CL, Loi S, **Graff SL**, Liu D, Rodrik-Outmezguine V, Sireci A, Rubenstein CS, Won H, Litchfield LM, Munoz M, Johnston S. Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial. *Oral Presentation*, General Session 3 on Friday, December 8, 2023, San Antonio Breast Cancer Symposium.
24. **Graff SL**, Tolaney S, Hart L, Razavi P, Janni W, Schwartzberg L, Danyliv A, Payan JCM, Ferrusi I, Adhikary RR, O’Shaughnessy J. Invasive disease-free survival (iDFS) as a surrogate for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth

- factor receptor 2–negative (HR+/HER2–) early breast cancer (EBC): a real-world analysis. *Poster Presentation*. 2023 San Antonio Breast Cancer Symposium.
25. Trapani D, Deshmukh SK, Wu S, Xiu J, Walker P, Advani P, Lin NU, Curigliano G, **Graff SL**, Nabhan C, Sledge GW, Tolaney SM, Leone JP. Molecular and immunological landscape of sex-based differences in breast cancer: a distinct disease in men. *Poster Spotlight Presentation*, San Antonio Breast Cancer Symposium December 7, 2023.
 26. Advani P, Deshmukh SK, Wu S, Andring J, Xiu J, Farrell A, Leone JP, Priya Jayachandran P, **Graff SL**, Oberley M, Sledge GW, Chanan-Khan A. Comprehensive Molecular and Immunological Characterization of Invasive Ductal Triple-Negative Breast Cancer. *Poster Presentation*, San Antonio Breast Cancer Symposium December 7, 2023.
 27. Advani P, Deshmukh SK, Wu S, Andring J, Xiu J, Farrell A, Trapani D, Torres ER, Graff SL, Radovich M, Sledge GW, Chanan-Khan A. Comprehensive Characterization of BCL2 Family Genes in Metaplastic Triple Negative Breast Cancer. *Poster Presentation*, San Antonio Breast Cancer Symposium December 7, 2023.
 28. Chang A, Singh K, **Graff SL**, Wang L, Yakirevich E, Wang Y. Is Oncotype DX Helpful in Clinical Decision Making for Invasive Micropapillary Carcinoma? *Poster Presentation*. United States and Canadian Academy of Pathology 2024 Annual Meeting
 29. Holder SL, Lagos G, Carneiro B, Mega A, DeSouza A, McKay RR, Elliott A, Nabhan C, **Graff SL**. An analysis of Proviral Insertion Site of Moloney Murine Leukemia Virus, PIM1, kinase expression and clinical outcomes in renal cell carcinoma. *American Association for Cancer Research 2024 Annual Meeting*
 30. **Graff SL**, Schmid P, Cristofanilli M, Cescon DW, Hovey T, Tse K, Vukovic P, O’Shaughnessy J. TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab versus Chemotherapy (CT) plus Pembrolizumab in Patients (pts) with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC) Miami Breast Cancer Conference (MBCC) 2024. March 7–10, 2024; Miami, FL, USA; Trials in Progress Abstract, Poster Presentation.
 31. Advani P, Deshmukh SK, Wu S, Andring J, Xiu J, Leone JP, Jayachandran P, **Graff SL**, Oberley M, Sledge GW, Chanan-Khan A. Comprehensive Molecular and Immune Profiling of Triple Negative Invasive Lobular Carcinoma. *Poster Presentation, American Association for Cancer Research 2024 Annual Meeting*
 32. Schmid P, Oliveira M, O’Shaughnessy J, Cristofanilli M, **Graff SL**, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. “TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab versus Chemotherapy (CT) plus Pembrolizumab in Patients (pts) with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC) *Trials in Progress Encore Poster*, European Society of Clinical Oncology Breast Cancer Congress 2024
 33. Desmedt C, Turner N, Johnston S, Arteaga CL, Sasano H, **Graff SL**, Loi S, Goetz MP, Liu D, Rodrik-Outmezguine V, Sireci A, Sandoval C, Won H, Litchfield LM, Munoz M, Chandarlapaty S. Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE, *Mini-Oral Presentation*, European Society of Clinical Oncology Breast Cancer Congress 2024
 34. Manogna D, Wu S, Deshmukh SK, Xiu J, Ehsani S, Gopalakrishnan R, Sandoval-Leon A, Ueno N, Sammons S, Sledge GW, **Graff SL**. “Genomic and Tumor Microenvironment Dynamics of Brain Metastases in Breast Cancer.” *Accepted for Mini-Oral Abstract Session*, American Society of Clinical Oncology Annual Meeting 2024

35. Bakow BR, Krause H, Elliott A, Soff GA, Trabolsi A, Antonarakis E, Oberley M, **Graff SL**. “The Prevalence of Sickle Cell Phenotype and its Association with Clinical Outcomes in Patients with Solid Malignancies.” *Accepted for Poster Presentation, American Society of Clinical Oncology Annual Meeting 2024*

ABSTRACTS IN SUBMISSION

1. Ghandali M, Srinivasan P, Wong E, Sobol RW, Zhou L, Carneiro B, **Graff SL**, El-Deiry SE. Tumor treating fields (TTF) shows efficacy in triple negative breast cancer (TNBC) cells and synergizes with PARP inhibitor Talazoparib. *Submitted American Association for Cancer Research 2024 Annual Meeting*
2. Kalinsky K, Bianchini G, Hamilton E, **Graff SL**, Park KH, Jeselsohn R, Demiri U, Martin M, Layman R, Hurvitz S, Sammons S, Kaufman P, Munoz M, Tseng LM, Knoderer H, Zhou Y, Ravenberg E, Litchfield LM, Wander S. “Abemaciclib plus fulvestrant for HR+, HER2-advanced breast cancer following progression on prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the Phase 3 postMONARCH study.” *Accepted, Oral Presentation, American Society of Clinical Oncology Annual Meeting 2024*
3. Loi S, Johnston S, Arteaga C, **Graff SL**, Chandarlapaty S, Goetz MP, Desmedt C, Sasano H, Liu D, Rodrik-Outmezguine V, Diereci A, Sandoval C, Won H, Litchfield LM, Turner N. “Prognostic utility of ctDNA dynamics in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).” *Accepted, Oral Presentation, American Society of Clinical Oncology Annual Meeting 2024*
4. Jayachandran P, Deshmukh SK, Wu S, Ribeiro JR, Kang I, Xiu J, Farrell A, Battaglin F, Spicer D, Soni S, Zhang W, Ashouri K, Millstein J, Ma CX, **Graff SL**, Radovich M, Sledge GW, Lenz HJ, Torres ER. “Molecular and immunological characterization of androgen receptor expression in different breast cancer subtypes.” *Submitted, American Society of Clinical Oncology Annual Meeting 2024*
5. Tarantino P, Rugo H, Curigliano G, O’Shaughnessy J, Janni W, Jhaveri K, Mouabbi J, Brufsky A, Hamilton E, O’Regan R, Santarsiero, L, Sum S, 13 Eleanor Sum, Scotchmer A, Ye F, **Graff SL**. Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis *Submitted, European Society of Medical Oncology Congress 2024*

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

1. “An Invitation to be Quiet No Longer,” **Graff, Stephanie**. ASCO Post, published online September 25, 2018. <http://www.ascopost.com/issues/september-25-2018/an-invitation-to-be-quiet-no-longer/>
2. “Gender Equity” **Graff, Stephanie**. ASCO Post, published online August 10, 2019. <https://www.ascopost.com/issues/august-10-2019/gender-equity/>
3. “Fostering a Culture of gender-based respect and inclusion in oncology” Duma N, Chapman C, **Graff SL**, Prowell TM, Knoll MA. Guest Editorial, *The Cancer Letter*. June 5, 2020. https://cancerletter.com/articles/20200605_7/
4. “The Ocean in Which We Float: Harassment in oncology is pervasive—just look at the data.” Guest Editorial, *The Cancer Letter*. June 11, 2021. **Graff SL**, Subbiah I, Markham MJ, Matt-Amaral LB, Close JL, Griffith KA, Jagsi R. https://cancerletter.com/guest-editorial/20210611_1/
5. “Exercise Is Easy Prescription for Patients Concerned About Potential Cognitive Effects of Chemotherapy.” **Graff, Stephanie**. *The Reading Room with MedPage Today* and

ASCO. Published Online October 5, 2021, at <https://www.medpagetoday.com/reading-room/asco/breast-cancer/94852>

6. “Sexual and Gender-Based Harassment in Oncology: It’s Not Just Time for Society to Heal—It’s Time for Us to Change.” Morgan, G, Choueiri TK, Dizon DS, Duma N, **Graff S**, Lewis M, Markham MJ. ASCO Daily News. Published Online October 6, 2021, at <https://dailynews.ascopubs.org/do/10.1200/ADN.21.200722/full/#.YV4EHPbSb5c.twitter>
7. “Young, Empowered, and Strong -- Young Women with Breast Cancer Engage With Digital Health to Improve Sensitive Care Needs.” **Graff, Stephanie**. The Reading Room with MedPage Today and ASCO. Published Online April 5, 2022, at <https://www.medpagetoday.com/reading-room/asco/breast-cancer/96306>
8. “Prospective Surveillance for Breast Cancer-Related Arm Lymphedema.” **Graff, Stephanie**. The Reading Room with MedPage Today and ASCO. Published Online April 5, 2022, at <https://www.medpagetoday.com/reading-room/asco/breast-cancer/98038>
9. Loprinzi, C, Accordino M, Bandla A, **Graff S**. “Development of the Chemotherapy-Induced Peripheral Neuropathy Cyrocompression Device” Scalp Cooling Summit: The White Papers, May 5, 2022. Available online for download at <https://scalpcoolingsummit.com/keynote-discussions/chemotherapy-induced-peripheral-neuropathy/>
10. “What Hodgkin Lymphoma Survivors Should Know About Mantle Radiation and Breast Cancer Risk” Dibble EH, **Graff SL**, Graves TA, Miller CJ. Cancer.Net, American Society of Clinical Oncology, June 14 2022. <https://www.cancer.net/blog/2022-06/what-hodgkin-lymphoma-survivors-should-know-about-mantle-radiation-and-breast-cancer-risk>
11. **Graff SL**, Bhave MA, Sharifi M, Fasching PA. Considering Adjuvant CDK4/6 Inhibitors: MonarchE and NATALEE in Clinical Practice, *ASCO Daily News*, Published online 17 AUG 2023 <https://dailynews.ascopubs.org/do/considering-adjuvant-cdk4-6-inhibitors-monarche-and-natalee-clinical-practice>
12. **Graff SL**, McGinn C, Showalter J. “Improving Outcomes for Women with Metastatic HER2-positive and HER2-Low Breast Cancer,” *Journal of the Advanced Practitioner in Oncology (JADPRO)* <https://doi.org/10.6004/jadpro.2024.15.3.x>

NON-PEER-REVIEWED: DIGITAL & PRINT MEDIA

1. “Scared of clinical trials? 7 reasons not to be.” **Graff, Stephanie**. KevinMD.com. Published online July 2, 2017. DOI: <https://www.kevinmd.com/blog/2017/07/scared-clinical-trials-7-reasons-not.html> Reprinted on the Sarah Cannon Cancer Blog and by Physician’s Weekly.
2. “Where physician and mother meet,” **Graff, Stephanie**. ASCO Connection. Published online June 13, 2017 DOI: <https://connection.asco.org/blogs/where-physician-and-mother-meet> Reprinted in “Best of ASCO Connection Blogs”, June 2018.
3. “The only perfect cancer statistic is an imperfect one”, **Graff, Stephanie**. KevinMD.com. published online May 30, 2017, DOI: <http://www.kevinmd.com/blog/2017/05/perfect-cancer-statistic-imperfect-one.html>
4. “This October, share the message of early breast cancer detection.” **Graff, Stephanie**. KevinMD.com. published online September 19, 2017. DOI: <http://www.kevinmd.com/blog/2017/09/october-share-message-early-breast-cancer-detection.html>
5. “Takeaways from the Women in Oncology Strategic Planning Retreat” **Graff, Stephanie**. ASCO Connection. Published online September 21, 2017 DOI:

- <https://connection.asco.org/blogs/takeaways-women-oncology-strategic-planning-retreat>
6. “Being a Physician-Patient Is a Double Edge Sword” **Graff, S** with Shanahan, K. ASCO Connection, Published online May 21, 2018. DOI: <https://connection.asco.org/blogs/being-physician-patient-double-edged-sword>
 7. “Conference High” **Graff S**. ASCO Connection, published online June 8, 2018. DOI: <https://connection.asco.org/blogs/conference-high>
 8. “Everything I Needed to Know, I Learned in a Cancer Clinic”, **Graff, Stephanie**. ASCO Connection, published online July 23, 2018. <https://connection.asco.org/blogs/everything-i-needed-know-i-learned-cancer-clinic>, re-released on KevinMD July 29, 2018 <https://www.kevinmd.com/blog/2018/07/the-most-valuable-lessons-in-life-can-be-learned-in-oncology.html>
Awarded APEX Award for Publication Excellence, Social Media – Single Blog Post. Communications Concepts, 2019; Best of ASCO Connections Blogs 15th Anniversary Special Edition 2024 ASCO Annual Meeting
 9. “The Blame Game: Cancer Is Not the Patient’s Fault,” **Graff, Stephanie**. ASCO Connection, published online February 11, 2019. <https://connection.asco.org/blogs/blame-game-cancer-not-patients-fault>
 10. “Honor National Women Physicians Day with Self-Care” **Graff, Stephanie**. ASCO Connection, published online February 1, 2019. <https://connection.asco.org/blogs/honor-national-women-physicians-day-self-care>. Reprinted in “Best of ASCO Connection Blogs”, June 2019.
 11. “Takeaways from American Society of Clinical Oncology 2021 (ASCO)”, **Graff, Stephanie** Dr Susan Love Foundation for Breast Cancer Research Blog. Published online July 6, 2021. <https://drsusanloveresearch.org/takeaways-from-american-society-of-clinical-oncology-2021/>
 12. “Cannabis & Breast Cancer: Seeing Through the Weed”, **Graff, Stephanie** Dr Susan Love Foundation for Breast Cancer Research Blog. Published online August 1, 2021. <https://drsusanloveresearch.org/cannabis-breast-cancer-seeing-through-the-weeds-by-stephanie-l-graff-md-facp/>
 13. “October: A Love-Hate Season”, **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online October 15, 2021. <https://drsusanloveresearch.org/october-a-love-hate-season-by-stephanie-l-graff-md-facp/>
Awarded APEX Award for Publication Excellence, Social Media – Single Blog Post. Communications Concepts, 2022
 14. “Giving Makes a House a Home” Graff, Stephanie. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online November 15, 2021. <https://drsusanloveresearch.org/giving-makes-a-house-a-home-by-stephanie-l-graff-md-facp/>
 15. “Key Takeaways: San Antonio Breast Cancer Symposium 2021.” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online November 15, 2021. <https://drsusanloveresearch.org/key-takeaways-san-antonio-breast-cancer-symposium-2021-by-stephanie-l-graff-md-facp/>
 16. “Find the ‘Pull’: A Reader’s Guide to Managing Career Transitions. **Graff, Stephanie**. ASCO Daily News. Published online February 1, 2022, at <https://dailynews.ascopubs.org/doi/10.1200/ADN.22.200837/full/>
 17. “Cure & Celebrations”, **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer

- Research Blog. Published online April 12, 2022 <https://drsusanloveresearch.org/cure-celebrations-by-stephanie-l-graff-md-facp/>
18. “Expanding Family Leave About Equity, Health.” Dibble, EH and **Graff, SL**. Editorial, *Providence Journal*. May 10, 2022. Available online at https://providencejournal-ri.newsmemory.com/?publink=276cef39a_1348482
 19. “Destiny Breast” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online June 8, 2022 at <https://drsusanloveresearch.org/destiny-breast-by-dr-stephanie-l-graff-md-facp/>
 20. “The Shock of Breast Implant Associate Lymphoma” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online August 20, 2022 at <https://drsusanloveresearch.org/the-shock-of-breast-implant-associated-lymphoma-by-dr-stephanie-l-graff-md-facp/>
 21. “The One with the Pie Crust” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online November 22, 2022. <https://drsusanloveresearch.org/the-one-with-the-pie-crust-by-dr-stephanie-graff/>
 22. “San Antonio Breast Cancer Symposium 2022” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online January 3, 2023 <https://drsusanloveresearch.org/what-makes-an-advocate-by-dr-stephanie-graff/>
 23. “What Makes an Advocate” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online March 1, 2023 <https://drsusanloveresearch.org/san-antonio-breast-cancer-symposium-2022-by-dr-stephanie-graff/>
 24. “Identifying and Addressing Implicit Bias in the Workplace,” *Journal of Oncology Navigation & Survivorship* 14(2):Feb 2023; Buffington, Mary based on the work of **Graff, Stephanie**. Published online February 20, 2023 at <https://journals-online.com/issues/2023/february-2023-vol-14-no-2?view=article&artid=4816:identifying-and-addressing-implicit-bias-in-the-workplace>
 25. “Bring On the Babies: The POSITIVE Trial, Pregnancy, and Breast Cancer” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online July 4, 2023 at <https://drsusanloveresearch.org/bring-on-the-babies/>
 26. “Reforms Urged to Bridge Gender Gaps in Cancer Care.” Quoted as **Graff SL**. *Cancer Discov* 2023; <https://doi.org/10.1158/2159-8290.CD-NB2023-0072>
 27. Best Practices for Detecting ESR1 Mutations in Metastatic Breast Cancer. **Graff, Stephanie**. ReachMD. Published online December 2023. <https://reachmd.com/programs/project-oncology/best-practices-for-detecting-esr1-mutations-in-metastatic-breast-cancer/16207/>

INVITED PRESENTATIONS

LOCAL

1. “Case Studies in Advanced Cardiac Life Support,” Expert Panel, St. Luke’s Hospital, May 21, 2008
2. “Lung Cancer”, University of Kansas Medical Center Core Curriculum, January 12, 2010.
3. “Breast Cancer Risk Reduction in the High-Risk Patient”, Research Medical Center Noon Conference, Kansas City, Missouri, September 2011
4. “Breast Health: Prevention & Risk Reduction”, Nursing education program, Research Medical Center, Kansas City, Missouri, October 21, 2011
5. “Simplifying Dense Breast Tissue & the Importance of Advanced Screening”, HCA Midwest Health Division Grand Rounds, Kansas City, MO, March 2021 (Virtual, COVID19)

6. “Conversations with the Authors Off Our Chests: A Candid Tour Through The World of Cancer,” panelist, Brown Cancer Center, Providence RI, November 2021
7. “Beyond Staging in Hormone Receptor Positive Breast Cancer: Genomics to Define Treatment & Prognosis” Brown Medicine Grand Rounds, Providence RI March 1, 2022
8. “Fostering Success in Research”, Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; May 19, 2022
9. “How to Navigate ASCO Annual Meeting” Hematology/Oncology Fellows Conference, Warren-Alpert School of Medicine, Brown University, Providence RI; May 19, 2022
10. “Metastatic Hormone Receptor Positive Breast Cancer”, Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; May 19, 2022
11. “Life After Training: A Casual Evening with Faculty,” Panel Discussion, Hematology/Oncology Fellows, Warren-Alpert School of Medicine, Brown University, Providence RI; May 27, 2022
12. “Redefining Breast Cancer,” Massachusetts General Hospital Multidisciplinary Breast Rounds, Boston, MA; May 31, 2022
13. “The 2% of Breast Oncology You Need to Know,” Brown Internal Medicine Noon Conference, Rhode Island Hospital, Providence, RI; September 16, 2022
14. “SABCS Updates” Hematology/Oncology Grand Rounds, Legorreta Cancer Center at Brown University, Providence RI, January 19, 2022
15. “Breast Cancer State of the Union”, Translational Disease Working Groups Strategic Retreat, Legorreta Cancer Center at Brown University, Providence RI, February 18, 2023
16. “Updates in Breast Oncology”, Translational Disease Working Group, Legorreta Cancer Center at Brown University, Providence RI, March 23, 2023
17. “Advancing ADCs,” Cancer Therapeutics Program, Legorreta Cancer Center at Brown University, Providence RI, April 7, 2023
18. “CIPN”, Oncology Advanced Practice Providers, Lifespan Health Center Monthly Meeting, Providence, RI. April 2023
19. “Hormone Receptor Positive Metastatic Breast Cancer,” Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; April, 2023
20. “CDK4/6 Inhibitors in Early-Stage Breast Cancer” Hem/Onc Grand Rounds, Legorreta Cancer Center at Brown University, Providence RI, January 11, 2024
21. “Hormone Receptor Positive Metastatic Breast Cancer,” Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; April 11, 2024
22. “Translational Science Principles: Breast Cancer TRDG Update” Translational Disease Working Groups Strategic Retreat, Legorreta Cancer Center at Brown University, Providence RI; May 24, 2024

REGIONAL

1. “New Insights on Non-Hodgkin’s Lymphoma”, Current Trends in Leukemia, Lymphoma and Myeloma; Stower’s Institute for Medical Research, Kansas City, Missouri, February 5, 2011
2. Moderator, University of Kansas Cancer Center Lung Cancer Symposium, Kansas City, Kansas, March 3, 2012.
3. “State of the Art: Breast Cancer Update,” Kansas City Southwest Clinical Society 90th Annual Fall Clinical Conference, Overland Park, Kansas, November 3, 2012

4. Moderator, University of Kansas Cancer Center Lung Cancer & Head and Neck Cancer Symposium, Kansas City, Kansas, March 9, 2013
5. “Oncologic Emergencies,” Kansas City Southwest Clinical Society Current Management in Critical Care, Overland Park, Kansas, May 2, 2013
6. “Cancer In Kansas City.” Served as expert panelist for live televised discussion on KCPT in conjunction with airing of Ken Burns’ documentary “The Emperor of All Maladies.” Kansas City, Missouri, April 2015.
7. “Genomics & Genetics: Breast Cancer in 2016”. Innovations in Oncology Conference, Kansas City, Missouri. October 2016.
8. “Estrogen Receptor Positive Metastatic Breast Cancer”, Break-out Sessions, Sarah Cannon Research Institute Annual Scientific Meeting, Nashville, Tennessee, March 4, 2017
9. “Breast Cancer Prevention and Diagnosis”, Southwest Clinical Society Fall Clinical Conference, Overland Park, Kansas, October 5, 2017.
10. “AJCC 8th Edition: Where Staging & Genomics Meet”, 2017 Bi-State Regional Education Meeting, Missouri State Tumor Registrars Association, **Keynote Address**, Riverside, Missouri, October 25, 2017.
11. “Metastatic Breast Cancer” OncLive State of Science Symposium, Kansas City, MO June 30, 2018 “If It’s Broken, Don’t Fix It: Targeting Cancer and DNA Repair,” Break-out Sessions, Sarah Cannon Research Institute Annual Scientific Meeting, Nashville, Tennessee, March 10, 2018
12. “TailorRx and Gene Expression in Modern Breast Cancer Care,” Oklahoma Society of Clinical Oncology Best of ASCO Review, Oklahoma City, OK, September 15, 2018
13. “Escalation and De-escalation of Treatment in Early-Stage Hormone Receptor Positive Breast Cancer,” OncLive State of Science Symposium, Nashville, TN, January 14, 2019
14. “Escalation and De-escalation of Treatment in Early-Stage Hormone Receptor Positive Breast Cancer,” OncLive State of Science Symposium, Overland Park, KS, February 2, 2019
15. “Highlights in Breast Cancers: ASCO 2019,” ASCO Direct™ Highlights: Kansas City, MO, June 2019
16. “Hormone receptor positive early-stage breast cancer” OncLive State of Science Symposium, Nashville, TN, January 2020.
17. *“Breast Cancer” Break-out Sessions, Sarah Cannon Research Institute Annual Scientific Meeting, Nashville, Tennessee, March 2020 (cancelled, COVID19)*
18. “Breast Cancer Screening and Risk Reduction: Management of the High-Risk Patient,” Bixby Symposium, October 2020 (Virtual, COVID19)
19. “Living the State Motto” **Keynote Address**, American Cancer Society Cancer Action Network Breakfast, November 2021, Providence RI
20. “Breast Medical Oncology: Where Are We Now?,” Not Your Grandma’s Mammogram: An Update In Breast Health for 2022, Rhode Island Women’s Health Initiative, Warren Alpert Medical School, May 25, 2022, Providence RI
21. “Alcohol & Breast Cancer—Intersections” Breas Cancer Translational Disease Group, Legorreta Cancer Center at Brown University, June 15, 2022, Providence, RI
22. “Research in Rhode Island” Panel Discussion, Moderator, 9th Annual Rhode Island Research Breakfast, American Cancer Society Cancer Action Network, October 7, 2022, Providence, RI
23. “Premenopausal Breast Cancer” & panel discussion, OncLive State of the Science Summit, Providence, RI, March 21, 2023 (Event Chair)
24. “ADCs: New Approvals & Emerging Directions” & panel discussion, OncLive State of the

- Science Summit, Providence, RI, March 21, 2023 (Event Chair)
25. “Case-based Roundtable in Breast Cancer,” Dartmouth NH, September 27, 2023
 26. “Disparities in Early Detection,” Middlesex Health, Middletown CT, September 28, 2023
 27. “Caring for the High-Risk Breast Cancer Patient into Adulthood” Consortium for New England Childhood Cancer Survivors (CONNCCS), Semi-Annual Meeting, Providence RI, May 8, 2024

NATIONAL

1. “Community Breast Oncology” Panelist. United States Food and Drug Administration Mini-Symposium, Bethesda MD, September 2017.
2. “From Sequencing to Social Media: Modern Era Oncology.” Seminar Series, Genospace, Boston MA, April 24, 2019.
3. “Building Your Brand.” Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
4. “A Social Media Toolkit to Enhance Your Career,” Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
5. “Women’s Leadership in the Pandemic: Balancing Leading, Achieving, and Innovation,” West Virginia University Women in Science & Health Grand Rounds, West Virginia University School of Medicine, Morgantown, WV (Virtual, COVID19) February 11, 2021
6. “Emerging Biomarkers in Breast Cancer – Looking Beyond ER, PR, and HER2,” Panelist, Food & Drug Administration Oncology Center of Excellence Mini-Symposium, Bethesda MD, March 31, 2021 (Virtual, COVID19)
7. “Advocating for Patients: Overcoming Obstacles in Care,” followed by “Unanswered Questions in Navigation” expert panel, National Consortium of Breast Centers Annual Meeting, Las Vegas NV, April 2021 (Postponed from April 2020, Virtual, COVID19)
8. “Impact of Pathways Implementation,” National Consortium of Breast Centers Annual Meeting, Las Vegas NV, April 2021 (Postponed from April 2020, Virtual, COVID19)
9. “Communication & Collaboration with Referring Physicians,” National Consortium of Breast Centers Annual Meeting, Las Vegas NV, April 2021 (Postponed from April 2020, Virtual, COVID19)
10. “Leading During Challenging Times” ASCO COVID-19 Professional Development Roundtable, June 11, 2020 (Virtual, COVID19)
11. “ASCO Women in Oncology Open Forum: Gender Bias and Harassment in the Workplace” Panelist, American Society of Clinical Oncology webinar, Alexandria, VA (Virtual), June 2021
12. “Breast Cancer Update in Triple Negative and HER2 Breast Cancers”, & Masters Roundtable panelist, Evolving Treatments for the Oncology Practice. Nashville, TN, June 2021
13. “NRG Oncology Social Media Workshop,” NRG Oncology Virtual Summer Meeting, July 26, 2021
14. “Targeted Therapies in Metastatic Breast Cancer” and Panel Discussion, 2021 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes, Binaytara Foundation, Salt Lake City, UT, October 2021
15. “Advanced Breast Cancer”, Best of ASCO 2021 – Providence, Providence, RI, October 2021
16. “Careers in Breast Cancer” San Antonio Breast Cancer Symposium 2023 Satellite Meeting, with Caris Precision Oncology Alliance, December 2021
17. “Create Collaboration to Expand Drug Development Initiatives: A Principal Investigator’s Perspective” (Keynote Address), Early Phase Site Strategy Virtual Summit, January 18, 2022

18. “Triple Negative Breast Cancer Grand Rounds: Practical Guidance for the Community Oncologist”, Kootenai Clinic Cancer Services, Coeur d’Alene, ID, January 26, 2022
19. “Collaborating with Community Providers for Program Success”, High Risk Breast Cancer Pre-Course, National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2022
20. “Implicit Bias: Identifying & Addressing” (Plenary Lecture), National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2022
21. “Relationship Building in the Multi-disciplinary Model”, National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2022
22. “Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2” Grand Rounds, Ascension Macomb-Oakland Hospital, Warren MI, April 22, 2022
23. “Triple Negative Breast Cancer and the Role of ADCs,” Grand Rounds, Rush Medical Center Grand Rounds, Chicago IL (Virtual), April 29, 2022
24. “Triple Negative Breast Cancer”, Grand Rounds, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis IN (Virtual), May 20, 2022
25. “Best Practices in HER2+ Metastatic Breast Cancer: Optimizing Combination Therapies” with panel discussion, Oncology Meeting Innovations/DAVA, (Virtual), September 13, 2022
26. “Implicit Bias”. Academy of Oncology Nurse & Patient Navigators (AONN+) Annual Navigation and Survivorship Conference, New Orleans, LA, November 3, 2022
27. “How I Treat Refractory Metastatic HR+/HER2- Metastatic Breast Cancer,” ASCO Expert Answers, Digital Web CME Module, Recorded February 10, 2023
28. “Mutational Landscape of HER2-Low Metastatic Breast Cancer” and “Key Takeaways, SABCs 2022”, Caris Precision Oncology Breast Diseases Working Group Meeting, Phoenix AZ (Virtual), February 28, 2023
29. “Simply Said: Communicating the Complexity of High-Risk Care with Patients: A Role Play”, High-Risk Breast Cancer Pre Course, National Consortium of Breast Centers 2023 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
30. “We The People: Building a Democratic High-Risk Program,” High-Risk Breast Cancer Pre Course, National Consortium of Breast Centers 2023 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
31. “Beyond Buzzwords: Including Inclusivity & Micro-interventions to Microaggressions” (Plenary Lecture), National Consortium of Breast Centers 2023 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
32. “Disparities in Breast Cancer Care,” Panel Discussion, National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
33. “Simone's Maxim for our Time” Panel Discussion, COVID-19 and Cancer Consortium Third Annual Retreat, Warren-Alpert Medical School of Brown University, Providence RI, March 31, 2023
34. “Evolving Strategies in Hereditary Cancer 2023: Examining Equity and Implicit Bias in Cancer Care,” Myriad Genetics Oncology Continuing Education Series, April 7, 2023
35. “The Promise of Oral SERDS” & Panel discussion, OncLive Institutional Perspectives in Cancer, Emory Winship Cancer Institute, Atlanta GA (Virtual), April 18, 2023
36. “ESMO Breast 2023 Key Takeaways”, Caris Precision Oncology Alliance National Breast Meeting, (Virtual) May 23, 2023
37. ASCO 2023 Breast Cancer Updates, Targeted Oncology and Oncology Brothers. June 2023, Virtual
38. “Breast Cancer Highlights from ASCO 2023”, Caris Precision Oncology Alliance Breast

- Cancer Working Group Meeting, (Virtual) August 22, 2023
39. “Breast Cancer”, Moderator, Best of ASCO 2023 Providence, Providence, RI, September 23, 2023
 40. “Breast Cancer Update” ASCO Direct, Cincinnati Cancer Advisors, Cincinnati OH, September 30, 2023
 41. “Moving Beyond the Binary Categorization of HER2 Status: Antibody-Drug Conjugate Therapy in Metastatic Breast Cancer,” teleECHO (Extension for Community Healthcare Outcomes), (Virtual) October 26, 2023
 42. “How I Manage Oligometastatic Disease”. Annual Savannah Symposium, Georgia Cancer Center. Savannah GA, October 27, 2023
 43. “Metastatic HER2+ Breast Cancer” JADPRO Live, Journal of the Advanced Practitioner in Oncology Annual Meeting, Orlando FL, November 11, 2023
 44. “Pivoting to New Paths – Charting a New Way Forward,” ASCO Professional Development Series for Women in Oncology, November 14, 2023, Virtual
 45. “Forging a Patient-Centered Collaborative Research Path: Insights & Discussion of Clinical Meaningfulness in Metastatic Breast Cancer with Clinicians, Patients, and Caregivers,” San Antonio Breast Cancer Symposium Satellite Symposium, December 6, 2023
 46. “Hormone Receptor-Positive Breast Cancer,” Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology. Research to Practice, Virtual. January 11, 2024
 47. Breast Cancer Updates. 5th Annual Guthrie Virtual P.A.U.S.E. (Physicians and Advanced Practice Providers United in Substantive Education) Summit, Guthrie Clinic of Northern Pennsylvania and Central New York (Virtual), February 19, 2024
 48. “Getting the Support You Need for a High Risk Breast Program”, National Consortium of Breast Cancer 2024 Annual National Meeting, Las Vegas NV, March 2024
 49. “What To Do At Home: Medical Oncology” National Consortium of Breast Cancer 2024 Annual National Meeting, Las Vegas NV, March 2024
 50. Fertility Preservation and Quality of Life in Premenopausal Patients With Breast Cancer, Ask The Experts Session (during ASCO Annual Meeting), Union League Club of Chicago, Chicago, IL, May 2024
 51. “Getting the Story *Write*: Narrative Medicine to Hear, Heal and Help” American Society of Clinical Oncology Annual Meeting, Chicago IL, June 2024 (*invited*)
 52. “Hormone Receptor Positive Breast Cancer” 2024 Upstate New York Cancer Symposium with Wilmont Cancer Institute and Roswell Park Cancer Center, Rochester NY; June 2024 (*invited*)

INTERNATIONAL

1. “How Close Is Too Close: Navigating Difficult Situations” and panel discussion, session: When Cancer Hits Close to Home: Treating Colleagues and Loved Ones, American Society of Clinical Oncology Annual Meeting 2018, Chicago, IL, June 4, 2018
2. “How to Prepare Fellows for Transition to Private Practice” and panel discussion, session: Training Program Directors’ Breakfast, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 2, 2019
3. “Potential Pitfalls of Community Cancer Research,” and panel discussion, session: Building a Sustainable Research Program in the Community Practice Setting: First Steps, Essential Priorities, and Pitfalls Every Investigator Should Know, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 2, 2019
4. “Mind the Gap”, Professional Development Poster Session Discussant, American Society of

- Clinical Oncology Annual Meeting, Chicago, IL (Virtual, COVID19), May 2020
5. “The Myth of Work Life Balance” Mexican Society of Oncology (Sociedad Mexicana de Oncología) International Oncology Congress, Mexico City, Mexico, October 2020 (Virtual, COVID19)
 6. “Gene Expression Signatures: Personalizing Early-Stage Breast Cancer,” Breast Cancer in Young –Modern Approaches and Challenges Conferences, Georgian School of Oncology, Tbilisi, Georgia (Virtual/COVID19), June 2021
 7. “Digital Advances in the Metastatic Breast Cancer Treatment Landscape” and Panel Discussion, Asian Pacific Oncology Summit (Virtual/COVID19), October 5, 2021
 8. Precision Care: Taking Aim at Collateral Damage, A Pre-San Antonio Breast Cancer Symposium 2021 Webinar and Panel Discussion with the Dr. Susan Love Foundation for Breast Cancer Research, December 3, 2021 (Virtual/COVID-19)
 9. “Development of CIPN Cyro-Compression Device”, (Keynote Discussion) Scalp Cooling Summit, May 5, 2022, Huddersfield, United Kingdom (Virtual, pre-recorded with live Q&A)
 10. Technology-Enabled Clinical Trials Using Electronic Health Record-Derived Real-World Data: Opportunities and Limitations”, DIA 2022 Global Annual Meeting, Chicago IL, Jun 2022
 11. “From the Panel to the Patient: Clinical Implications of Germline Testing for Breast Cancer,” Poster Discussant, Prevention, Risk Reduction, and Hereditary Cancer Session, 2022 American Society of Clinical Oncology Annual Meeting, Chicago IL, June 6, 2022
 12. “Emerging Trends & Controversies Guiding Breast Cancer Research,” 3rd Annual OncoAlert Colloquium, January 23-28, 2023. Virtual. Available On Demand at <http://www.oncoalert360.com/the-oncoalert-colloquium-2022.html>
 13. “Meet the Experts: Scalp Cooling and Cryotherapy: Latest Advancements to Address Chemotherapy-Induced Alopecia and Peripheral Neuropathy” Multinational Association of Supportive Care in Cancer (MASCC), Japanese Association of Supportive Care in Cancer (JASCC), and International Society of Oral Oncology (ISOO) 2023 Annual Meeting, Nara, Japan, June 23, 2023
 14. “Multidisciplinary Perspectives in Breast Cancer”, The Multidisciplinary Perspectives in Breast Cancer, OncoAlert and Mirrors in Medicine, Brussels, Belgium, October 6, 2023
 15. “One Size Does Not Fit All: Personalizing Endocrine Therapy Recommendations in Breast Cancer.” Multinational Association of Supportive Care in Cancer, Webinar/Virtual, November 30, 2023
 16. “Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer” Poster *Spotlight Discussion*, “Prognostic and predictive uses of cell free DNA,” Wednesday, December 6, 2023, San Antonio Breast Cancer Symposium 2023
 17. “Treatment post CDK 4/6 inhibitors” Session Moderator, San Antonio Breast Cancer Symposium® (SABCS) 2023, San Antonio TX
 18. “HER2-Positive Metastatic Breast Cancer: The Year in Review 2023,” 4th Annual OncoAlert Colloquium in partnership with ASTRO/ESSO/MASCC/ESGO/SIOG, February 4-10, 2024. Virtual.
 19. “Breaking New Ground with CDK4/6 Inhibitors: Case-based Discussions on Treatment Decisions in HR+/HER2- Breast Cancer”, ESMO Breast Cancer, Berlin

Germany, May 16, 2024

DIGITAL

1. “The Cattle Don’t Care” Journal of Clinical Oncology Cancer Stories: The Art of Oncology Podcast Series with Lidia Schapira, MD. Published online November 17, 2019. <https://aopodcast.libsyn.com/the-cattle-dont-care>
2. “Advocacy, Patient Education, and Outreach for Breast Cancer Research” with Dr Susan Love, Dr. Charu Aggarwal, and Dr. Jack West. Beyond the Journal Podcast, February 22, 2021 https://beaconmedic.com/drs-susan-love-and-stephanie-graff-on-advocacy-patient-education-and-outreach-for-breast-cancer-research-btj-009/btj-009_susan_love_stephanie_graff_thumb/
3. “Overcoming Uncertainty and Embracing Growth.” Oncology Overdrive Podcast on Healio with Dr. Shikha Jain, June 15, 2021. <https://www.healio.com/news/hematology-oncology/resources/oncology-overdrive/episode-36>
4. “Advances in Breast Cancer” Caris Molecular Minute Podcast with Dr. Chadi Nabhan, October 2021 <https://soundcloud.com/user-171589389/interview-with-dr-stephanie-graff-advances-in-breast-cancer>
5. “Breast Cancer Research” Brown Medicine Moving the Needle Podcast, November 18, 2021 <https://brownmed.org/news/brown-medicine-moving-the-needle-podcast-breast-cancer-research-with-dr-graff-ep-2/>
6. “Breast Cancer: From Diagnosis to Treatment”, MEDTECH Live Panel on Clubhouse with Amit Goldman, Dr. Yan Leyfman, Chirag Shah, and Dr. Margaret Gatti-Mays, December 2021
7. “GRASping the Importance of Patient Advocacy.” Oncology Overdrive Podcast on Healio with Dr. Shikha Jain, December 14, 2021, <https://www.healio.com/news/hematology-oncology/resources/oncology-overdrive/episode-45>
8. “Metastatic Triple Negative Breast Cancer,” with Dr. Laura Salama and Dr. Charles Milrod, Tumor Board Tuesday. Live Tweetchat with Integrity Continuing Education. Full transcript available at https://twitter.com/TumorBoardTues/status/1588712182514323458?s=20&t=iG-2wdQZ0_nRiH0UiGipaQ, November 8, 2022
9. “People Like Us” Journal of Clinical Oncology Cancer Stories: The Art of Oncology Podcast Series with Lidia Schapira, MD available at <https://aopodcast.libsyn.com/people-like-us-what-it-means-to-be-an-outsider-in-oncology>, published online November 8, 2022
10. “Understanding Modern Medical Centers: Beyond Simone—Intersectional Maxims for a New Era” Journal of Clinical Oncology Podcast Series with Shannon N. Westin, MD, available at <https://jcopodcast.libsyn.com/intersectional-maxims-for-a-new-era-in-modern-medicine>. Published online December 9, 2022
11. “SABCS 2022: The Year of the Updates” Stephanie Graff, MD, Manali Bhawe, MD, Aditya Bardia, MD, MPH; OBR Oncology, published online Jan 10, 2023 at <https://www.obroncology.com/leading-thoughts/sabcs-2022-the-year-of-updates>
12. Outstanding Questions About Oral SERDs and Capivasertib Stephanie Graff, MD, Manali Bhawe, MD, Aditya Bardia, MD, MPH; OBR Oncology, published online Jan 26, 2023 at <https://www.obroncology.com/leading-thoughts/outstanding-questions-about-oral-serds-and-capivasertib>
13. “Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff MD FACP” Oncology Times Podcast with Sarah LaCorte, published online April 13, 2023 at <https://journals.lww.com/oncology->

- times/pages/collectiondetails.aspx?TopicalCollectionId=64
14. “The Bottom Line on What Elacestrant’s Approval Means for Metastatic Breast Cancer Care” Stephanie Graff, MD, Manali Bhawe, MD, Aditya Bardia, MD, MPH; OBR Oncology posted Apr 13, 2023 at <https://www.obroncology.com/leading-thoughts/the-bottom-line-on-what-elacestrants-approval-means-for-metastatic-breast-cancer-care>
 15. “More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists” Stephanie Graff, MD, and Robert A. Figlin, MD, FACP, OBR Oncology posted online Jul 18, 2023 at <https://www.obroncology.com/video/more-cage-rattling-less-talking-susan-loves-lessons-for-oncologists>
 16. “Advanced and Metastatic Breast Cancer: Health Disparities and Underrepresentation of Black Women in Clinical Trials” Medscape InDiscussion: Advanced and Metastatic Breast Cancer Podcast, Episode 5. Published on 8 Aug 2023 at: <https://www.medscape.com/viewarticle/982650>
 17. “Hormone Receptor Positive Breast Cancer: Year In Review” with Dr. Erica Mayer, Dr. Neil Love, Research to Practice. Published Online January 31, 2024. Available at <https://www.researchtopractice.com/YiR2023/HRPosBC/Video/1?playlistIndex>
 18. “A “Tiebreaker” for Adjuvant CDK4/6 Inhibitors in Early Breast Cancer?” Dr. Erin Francis Cobain, Dr. Manali Bhawe; OBR Oncology. Published Online May 8, 2023 at <https://www.obroncology.com/leading-thoughts/a-tiebreaker-for-adjuvant-cdk4-6-inhibitors-in-early-breast-cancer>
 19. “When to Treat Non-TNBC Like It’s TNBC? “Trust Your Gut” with Dr. Erin Francis Cobain, Dr. Manali Bhawe; OBR Oncology. Published Online March 22, 2024 at <https://www.obroncology.com/leading-thoughts/when-to-treat-non-tnbc-like-its-tnbc-trust-your-gut>

COMMUNITY & PATIENT FACING

1. “Frankly Speaking About Cancer: Take Control of SGI Effects with Medicine, Mind & Body,” Expert Panel Discussion, Gilda’s Club Kansas City, Kansas City, Missouri, January 23, 2012
2. “Intersection of the American Cancer Society and Clinical Oncology Practice” 2018 American Cancer Society National Volunteer and Staff Leadership Summit, Dallas TX, February 8, 2018 (**Keynote Address**)
3. “Liver & Lung Metastases”, Living Beyond Breast Cancer 2019 Thriving Together Metastatic Conference, Philadelphia, PA, April 7, 2019.
4. “Breast Cancer Case Rotations,” ASCO Advantage and Cancer.Net “Cancer Basics for People with Cancer, Survivors, and the Public,” Alexandria VA, November 2019.
5. “Cancer Basics: Testing, Staging, and Grading” ASCO Advantage and Cancer.Net “Cancer Basics for People with Cancer, Survivors, and the Public,” Alexandria VA, November 2019.
6. “Candid Conversations: Mets, Sex, and Side Effects,” Panelist, San Antonio Breast Cancer Symposium Satellite Symposium, San Antonio TX, December 2019,
7. “Treatment of Hormone Receptor Positive Metastatic Breast Cancer,” Living Beyond Breast Cancer Metastatic Breast Cancer Summit, Philadelphia, PA, June 2020 (Virtual, COVID19)
8. “Male Breast Cancer & Aromatase Inhibitors, Male Breast Cancer Coalition Summit, Kansas City, MO, May 2020 (Virtual, COVID19),
9. “Searching for Unicorns: Exceptional Survivors and Responders”, Our MBC Life Podcast, March 1, 2021. <https://www.ourmbclife.org/episodes/searchingforunicorns>
10. “The Breast Cancer and COVID-19 Conundrum” Webinar, Dr. Susan Love Foundation for Breast Cancer Research, Encino, CA (Virtual), April 2021

11. “MonarchE & Male Breast Cancer,” Male Breast Cancer Coalition Summit, August 2021 (Virtual, COVID19)
1. “Changing Standards in the Treatment of Breast Cancer” Passport to Survivorship, Gloria Gemma Breast Cancer Research Foundation, Pawtucket, RI, August 2021 (Virtual, COVID19) “World Breast Cancer Research Day”, Live Panel, Instagram Live with Sheetal Sheth, August 2021
2. “Med-IQ: Breast Cancer Screening & Navigating the Diagnosis”, Live Panel, Instagram Live with TomikaTalks, October 2021
12. “Frequently Asked Questions Answered” and “Questions Cancer Doctors Wished Patients Asked”, EMPOWER Cancer Patients, Total Health Conferencing, October 2021 (Virtual, COVID19)
13. “Training Thru Treatment: Fitness and Movement After a Breast Cancer Diagnosis” Webinar, Dr. Susan Love Foundation for Breast Cancer Research, April 14, 2022, West Hollywood, CA
14. “Understanding Progression” Our MBC Life. Published Online 21 Apr 2022 at <https://www.ourmbclife.org/episodes/understanding-progression>
15. “Life Support: Clinical Trials for MBC. How Patients with Health and Racial Disparities Can Gain Access.” In partnership with Infinite Strength at Smilow Cancer Hospital, Yale University, New Haven, CT, June 2022
16. “Breaking Down Common Misunderstandings of Lymphedema” Webinar, Dr. Susan Love Foundation for Breast Cancer Research, June 16, 2022, West Hollywood, CA
17. “Her2-Low and Behold” Passport to Survivorship, Gloria Gemma Breast Cancer Research Foundation, Pawtucket, RI, October 2022
18. “The Cost of Breast Cancer” Financial Feminist Podcast with Tori Dunlap. Published October 4, 2022 at <https://herfirst100k.com/financial-feminist-show-notes/cost-of-breast-cancer>
19. “ASCO 2022: When The Dust Settles, Will ADCs Change MBC?” Our MBC Life Podcast, published online November 2, 2022 with Hope Rugo and Stephanie L. Graff, available at <https://www.ourmbclife.org/episodes/when-the-dust-settles>
20. “Clinical Trials in Breast Cancer” DiepCJourney Podcast with Terri Coutee, available at <https://directory.libsyn.com/episode/index/show/diepcjourney/id/25038582>, published online 11/18/2022
21. “ASCO 2022: When The Dust Settles, Will ADCs Change MBC?” Our MBC Life Podcast, published online November 22, 2022 with Sara Hurwitz, Kevin Kalinsky, and Stephanie L. Graff, available at <https://www.ourmbclife.org/episodes/when-the-dust-settles-part-two>
22. “Advancing Research in Rhode Island and the TP53 Story,” Providence Making Strides Against Breast Cancer Walk, New England American Cancer Society, Providence RI, October 22, 2022
23. “SABCS 2022 Key Take-Aways” Breastcancer.org Research Podcast. Recorded December 8, 2022. Published online December 13, 2022 at <https://www.breastcancer.org/podcast/sabcs-2022-key-take-aways>
24. “Breast Cancer, Patient Advocacy and More.” Get Real Health with Dr. Chana Davis. Recorded February 9, 2023, available online at <https://podcasts.apple.com/ca/podcast/get-real-health-with-dr-chana-davis/>
25. “Recent Advances, Controversies, and Emerging Trends in MBC” Our MBC Life Podcast, published online May 31, 2023, available at <https://www.ourmbclife.org/episodes/rtac-current-trends-and-controversies>
26. ASCO23 Wrap-Up. Breastcancer.Org Research Podcast published online June 7, 2023,

- available at <https://www.breastcancer.org/podcast/asco-2023-takeaways>
27. "NATALEE, SONIA, X-7/7—Findings from ASCO23" Oncology Brothers and Targeted Oncology, Published online 15 June 2023 at <https://oncbrothers.com/breast-asco2023/>
 28. "OMBCL Shorts: Dr. Stephanie Graff and Her Steps for Those Newly Diagnosed with MBC." Our MBC Life, published online 17 June 2023 at <https://www.ourmbclife.org/episodes/ombcl-shorts-dr-graff>
 29. "The Medical Minute - Ep. #74 - ASCO Direct™: A Patient Perspective" ft. Dr. Stephanie Graff, Cincinnati Cancer Advisors YouTube Channel, Virtual/Cincinnati OH, published online July 19, 2023 at https://www.youtube.com/watch?v=9a_lyKlnilg
 30. "Chemotherapy Induced Peripheral Neuropathy" 2023 Bret Miller 1T Male Breast Cancer Happens Virtual Conference, November 2, 2023
 31. "SABCS Key Highlights 2023", Living Beyond Breast Cancer Virtual Webinar, December 12, 2023
 32. "Metastatic Breast Cancer; Male Breast Cancer; Tumor & Immune Microenvironment," GRASP Poster Walkthroughs, San Antonio Breast Cancer Symposium, Virtual, December 15, 2023
 33. "On the Ground at SABCS: Clinical Meaningfulness Poster Walk-Thru" Triple Negative Breast Cancer Foundation. Published online December 14, 2023 at <https://tnbcfoundation.org/about-us/our-events/your-guide-to-the-2023-san-antonio-breast-cancer-symposium-2/on-the-ground-at-sabcs-2>
 34. "All Cancers; Brain Metastasis; Leptomeningeal Disease; HER3 Antibody-Drug Conjugates; Clinical Trials" GRASP Poster Walkthroughs, American Society of Clinical Oncology, Virtual, June 13, 2024

CLINICAL RESEARCH EXPERIENCE

Includes ongoing clinical trials and/or negative trials not otherwise published; published studies have been removed

1. A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of platinum-based chemotherapy. Sub-Investigator
2. 10043P: A Prospective Study of Clinical Outcomes for the Pathwork "Tissue of Origin Test." Sub-Investigator
3. A Phase 2 Randomized Open-label Study of MED 551 in Adults with Relapsed or Refractory DLBCL. (NCT01453205; MedImmune LLC) Sub-Investigator
4. A randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF with Triple Negative breast cancer (BRE-273; TapImmune) Principal Investigator
ClinicalTrials.Gov updated to reflect "Futility analysis did not support continuation analysis of this trial" 15 DEC 2022 <https://classic.clinicaltrials.gov/ct2/show/NCT02978222>
5. A phase III, randomized, placebo-controlled, multicenter study of the efficacy and safety of atezolizumab plus chemotherapy in the treatment of early-relapsing locally recurrent inoperable or metastatic triple-negative breast cancer (NCT03371017, BRE 304, Impassion132; Genentech) Principal Investigator
6. A Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations (NCT02795156, PRO 10, Sarah Cannon Research Institute), Principal Investigator

7. An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer (FORTRESS; NCT03786094 BRE 346; Polyphor Ltd), Principal Investigator
Negative press release issued by sponsor: <https://spexisbio.com/news/corporate-news-details/?newsid=2129439>
8. A Phase III Randomized Double-Blind Placebo Controlled Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib compared with Letrozole combined with Palbociclib in patients with estrogen receptor positive, Her2 negative locally advanced or metastatic breast cancer (NCT04546009, BRE352, persevERA; Hoffman-Roche), Principal Investigator
9. A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation (NCT04251533, BRE 353, Novartis), Principal Investigator
10. A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-04, NCT04539938, BRE 358, SeaGen), Principal Investigator
11. DFCI Elevate: Improving Outcomes for Older Patients with Breast Cancer -a Longitudinal Cohort and Patient Engagement Study (NCT03818087; Site Sub-Investigator)
12. DFCI VICTORY: A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients with Early-Stage OR Newly Diagnosed Metastatic Disease: VICTORY (Sub-Investigator)
13. Improving Breast Cancer Patient Distress Scores with Incorporation of Online Therapeutic Platform, BrUOG 402 (Sub-Investigator)
Study terminated by sponsor
14. postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy, I3Y-MC-JPEF (Principal Investigator, **Global Steering Committee**)
15. LS-P-Destiny07—A Phase 1b/2 Multicenter, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07), Principal Investigator
16. A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (GS592-6173, Gilead, ASCENT-04), Principal Investigator
17. STOP CIPN: Randomized Trial of Limb CryocompreSsion versus ConTInuous COmPression versus Low Cyclic Compression for the Prevention of TaxaneInduCed PerIPheral Neuropathy (SWOG-S2205, NCT05642611), **SWOG Community Chair**,

Principal Investigator

18. A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast02, AstraZeneca), Principal Investigator
19. Real-world economic outcomes and impact on work productivity associated with treatment induced adverse symptomatic events in patients with hormone receptor positive metastatic breast cancer treated with CDK4/6 inhibitors. (BrUOG 417), Principal Investigator
20. Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (SWOG S2013, NCT04871542), Sub-Investigator
21. A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSEssment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib (Alliance, NCT05812807) Sub-Investigator
22. A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (EMBER-4, J2J-MC-JZLH; Eli Lilly) Principal Investigator
23. A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03; Astra-Zeneca, SWOG Clinical Trial Partnerships); Principal Investigator
24. A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Durvalumab compared with Pembrolizumab in combination with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel/Gemcitabine+Carboplatin) in Patients with PDL1 positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05), **Global Steering Committee and US Investigator for the FDA submission**
25. Phase 1, 2-part, Multicenter, First-in-human Dose-escalation and Dose-expansion Study of DS-1103a Combination Therapy in Subjects with Advanced Solid Tumors (DS1103-074, COAST; Daiichi Sankyo, NCT05765851), Principal Investigator
26. A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in broader and closer to real-World patient populations in stage II and stage III Early breast cancer (WIDER, Novartis, NCT05827081) **Co-Chair, Global Steering Committee**
27. S2212, Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer, A Randomized Phase III Study (SCARLET, SWOG S2212, NCT05929768), Sub-Investigator
28. A Phase III, Randomized, Open-Label Study Evaluating Efficacy And Safety Of Giredestrant Compared With Fulvestrant, Both Combined With A Cdk4/6 Inhibitor, In Patients With Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer With Resistance To Prior Adjuvant Endocrine Therapy (LS-P-pionERA)
29. LS-P-POPPY: A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors, Sub-Investigator

TEACHING, ADVISING and MENTORING ROLESHigh School Students

1. Dahlia Pahlavi, 2022-2023
Barrington High School, Barrington RI
Project: Language Bias in Medicine
**Early Admission to Brown University*

Undergraduate Students

1. Emma Safran, BA, 2022-2023
Project: A multicenter retrospective study on the prognostic impact of pregnancy in women with history of BRCA mutated breast cancer. Published: Lambertini M, Blondeaux E, Agostinetti E, et al. BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. JAMA. 2024 Jan 2;331(1):49-59.
**Accepted to University of New England School of Medicine*

Graduate Students

1. Roxanne Wood, BA, CCRC, MPH Candidate
Brown University School of Public Health
Project: Implementing Collection of Sexual Orientation and Gender Identity (SOGI)

Medical Students

1. Sabrina Arezo, MS, 2022-
Brown University
Mentor, Doctoring Mentor Program 2022-2023
Mentor, Advanced Clinical Mentorship in Internal Medicine, 2023-2024
Project: Implementing Collection of Sexual Orientation and Gender Identity (SOGI)
Project: Updates in Systemic Treatment of Hormone Receptor-positive Early-Stage Breast Cancer, Current Treatment Options in Oncology, (Invited Review), In Progress
2. Emilija Sagaityte, MS, 2022- 2023
Brown University
Project: FTO Inhibition in Breast Cancer Brain Metastases; accepted "The Role of RNA Epitranscriptomics and the RNA Fat Mass and Obesity-Associated Demethylase in Triple Negative Breast. Advances in Breast Cancer Research, 2023 (12)
3. Parker Haddock, 2024 -
Brown University
Mentor, AMS Summer 2024 Program & Scholarly Concentration
*Project: HOLIDAAAY Care Study: **H**oliday **O**n-call **I**nfusion, **D**elays, **A**dmissions, **A**ccess and **Q**ualit**Y** **C**are Study*

Residents

1. Anna D. Louie, MD, 2021-
Department of Surgery Research Fellow, Brown University; Surgery Resident, Duke University
Project: Mutational landscape and immune infiltration of breast cancer metastases to gynecologic and other organs. Accepted as a Spotlight Poster Presentation to the 2021 San Antonio Breast Cancer Symposium, Wednesday December 6, 2021.
Louie AD, Bansal R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR,

Chalasanani P, El-Deiry WS, Dizon DS, Graff SL Genomic characterization of breast cancer by metastatic site and impact of variable co-expression of genomic mutations including CDH1 and PIK3CA on survival. *Manuscript in submission.*

2. Gerneiva Parkinson, MD, 2021-2024
Internal Medicine Resident
Brown University-Warren Alpert Medical School
Project: Investigating HBOC Germline Mutations in Trinidad and Tobago Breast Cancer Patients: Integrating Research into Existing Clinical Infrastructure, ongoing
Project: Genomic predictors of response in BRCA-mutated Breast Cancer, Ongoing
**Matched Hematology/Oncology Fellowship Stanford University, Palo Alto, CA*
3. Jessica Gonzalez, MD 2022-
Internal Medicine Resident, Arts & Medicine Track Brown University-Warren Alpert Medical School
Projects: Radiation Induced Sarcoma Presenting as an Anterior Mediastinal Mass with Pericardial Invasion
4. Stephanie Haddad, MD, 2022- 2024
Internal Medicine Resident
Brown University/Kent Hospital Internal Medicine Residency Program, Warwick, RI
Project: Haddad SA, Dizon DS, Graff SL. Sequencing systemic therapy in hormone-receptor positive metastatic breast cancer: a modern paradigm. *Chin Clin Oncol.* 2023 Aug;12(4):42. doi: 10.21037/cco-23-22. Epub 2023 Aug 10. PMID: 37574571.
Project.: Safety and Efficacy of KEYNOTE-522 in combination with anti-retroviral therapy in a patient with HIV and triple-negative breast cancer. Haddad, SA, Graff SL, Wang Y, Taneja C, Leonard K, Fenton MA *Clinical Case Studies*, 2023 San Antonio Breast Cancer Symposium 2023 Poster Presentation, *Case Report Publication In Progress*
**Matched Hematology/Oncology Fellowship at University of Texas-San Antonio, San Antonio, TX*
5. Jane Lock, MD PhD, 2024 –
Internal Medicine Resident
Brown University-Warren Alpert Medical School
Projects: In Development

Medical Oncology & Hematology Fellows

1. Rani Chudasama, MD 2021-2023
Division of Hematology/Oncology
Brown University
Project: Mutational landscape and immune infiltration of breast cancer metastases to gynecologic and other organs. *Accepted as a Spotlight Poster Presentation to the 2021 San Antonio Breast Cancer Symposium, Wednesday December 6, 2021.*
Project: Mutational landscape of Her2 low metastatic breast cancer, *Abstract accepted to special poster session, San Antonio Breast Cancer Symposium, 2022*
**Accepted position as Assistant Professor of Medicine, Hematology/Oncology Division, Duke University*
2. Laura Salama, MD 2021- 2023
Division of Hematology/Oncology
Brown University

Project: Evaluating Use of Twitter Spaces for Breast/Gynecology Oncology Journal Club

3. Brianna Bakow, MD 2022-present
Division of Hematology/Oncology
Brown University
Project: “The Prevalence of Sickle Cell Phenotype and its Association with Clinical Outcomes in Patients with Solid Malignancies.” *Submitted*, American Society of Clinical Oncology Annual Meeting 2024
4. Dharmini Manogna, MD 2023- present
Tulane University
Project: “Genomic and Tumor Microenvironment Dynamics of Brain Metastases in Breast Cancer.” *Submitted*, American Society of Clinical Oncology Annual Meeting 2024
5. Ahmed Khalil, MD 2023- present
Division of Hematology/Oncology
University of Maryland
Project: “Optimizing the Oncology Ecosystem: Addressing Barriers Between Community and Academic Oncologists.” *Submitted*, American Society of Clinical Oncology Annual Meeting 2024
6. Ghazal Kango, MD 2023- present
Division of Hematology/Oncology
University of Maryland
Project: “Optimizing the Oncology Ecosystem: Addressing Barriers Between Community and Academic Oncologists.” *Submitted*, American Society of Clinical Oncology Annual Meeting 2024

Assistant Professors

1. Maria Constantinou, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Brown University
Project: Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors, SWOG S2013
2. Sabrina Witherby, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Brown University
Project: Evaluating Use of Twitter Spaces for Breast/Gynecology Oncology Journal Club, ongoing
3. Sheldon Holder, MD, PhD
Assistant Professor of Pathology and Laboratory Medicine
Brown University
Project: Understanding PIM1 expression in isolation and against CDK4/6 or mTOR inhibition in breast and kidney cancers, *accepted ESMO Congress 2023, AACR Annual Meeting 2024*
4. Emily Hsu, MD

Assistant Professor of Medicine
 Division of Hematology/Oncology
 Brown University

Project: In Development, Optimizing CDK4/6 Inhibitors in Hormone-Receptor Positive Metastatic Breast Cancer, as part of Robert A. Winn Career Development Award

Project: Updates in Systemic Treatment of Hormone Receptor-positive Early-Stage Breast Cancer, Current Treatment Options in Oncology, (Invited Review), In Progress

Associate Professors

1. Mary Anne Fenton, MD

Associate Professor of Medicine
 Division of Hematology/Oncology
 Brown University

Project: Fenton MA, Tarantino P, Graff SL. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Curr. Oncol. 2023, 30(12), 10211-10223; <https://doi.org/10.3390/currenocol30120743>

National Advising/Mentoring

1. American Society of Clinical Oncology Annual Meeting Career Mentoring

- a. Ragisha Gopalakrishnan, MD—2019
 Hematology/Medical Oncology Fellow
 Vanderbilt University, Nashville TN
- b. Chrystal Landry, MD—2019
 Breast Oncologist
 Northwell Health, Lake Success, NY
- c. Maria Garcia-Jimenez, MD/MHS—2021
 Clinical Instructor of Medicine
 Division of Hematology/Oncology, UCLA David Geffen School of Medicine
- d. Rahul & Rohit Gosain—2022
 “Oncology Brothers”
- e. Prarthna Bhardwaj, MD, FACP—2022
 Hematology/Medical Oncology Fellow
 UMass Chan-Baystate, Springfield, MA
- f. Shafia Rahman, MD—2022
 Hematology/Medical Oncology Fellow
 The Ohio State University James Cancer Center, Columbus OH
- g. Mazie Tsang, MD, MS—2023
 Assistant Professor, Hematology/Medical Oncology/Palliative Care
 Mayo Clinic School of Graduate Medical Education, Phoenix, AZ
- h. Shipra Gandhi, MD—2023
 Assistant Professor of Oncology
 Roswell Park Comprehensive Cancer Center, Buffalo, NY
- i. Arya Mariam Roy, MD—2023
 Hematology/Medical Oncology Fellow
 Roswell Park Comprehensive Cancer Center, Buffalo, NY

2. American Society of Clinical Oncology Virtual Mentoring Program: ASCO’s Virtual Mentoring Program pairs members with a mentor outside of their institution through

virtual technology to address unmet career development needs of trainees, residents, and early-to-mid-career oncologists over a 1-year mentor commitment.

- a. Jasmine Kamboj, MD—2024-2025
Mayo Clinic, Rochester MN
3. Career Development Lectures & Workshops
 - a. “Negotiation Skills: Getting What You Need” Women’s Networking Center, American Society of Clinical Oncology Annual Meeting 2018, Chicago, IL, June 2, 2018
 - b. “Presentation Skills: How to Give a Good Talk,” Trainee & Early Career Oncologist Lounge, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 2, 2019
 - c. “How to Negotiate Successfully for What Matters,” Women’s Networking Center, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 1, 2019
 - d. “Building Your Brand.” Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
 - e. “A Social Media Toolkit to Enhance Your Career,” Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
 - f. *“Landing Your First Job” Trainee & Early Career Oncologist Lounge, American Society of Clinical Oncology Annual Meeting 2020, Chicago, IL, June 2020 (Cancelled, COVID-19)*
 - g. “A Day In The Life of an Oncologist”, Oncology Summer Internship Program, American Society of Clinical Oncology webinar, Alexandria, VA (Virtual), June 2021
 - h. “Careers in Breast Cancer” San Antonio Breast Cancer Symposium 2023 Satellite Meeting, with Caris Precision Oncology Alliance, December 2021
 - i. “Career Transitions In Oncology”, ASCO Women In Oncology Fireside Chat, panelist, Virtual, Arlington VA, December 2021
 - j. “Beyond Imposter: Celebrating Your Confidence and Success at Work”, Women’s Networking Center, American Society of Clinical Oncology Annual Meeting, Chicago IL, June 6, 2022
 - k. National Fellows Forum—Breast Cancer, San Antonio Breast Cancer Symposium with OncLive, **Chair**, August 2023-December 2023: *Developed curriculum, served as mentor to 6 selected fellows; reviewed submitted abstracts; provided feedback on research concepts and presentations; network across 30 fellows to facilitate career development; presented to forum on career development.*
 - l. Mentorship & Sponsorship Roundtable Discussion”, Women’s Networking Center, American Society of Clinical Oncology Annual Meeting 2023, Chicago IL, June 5, 2023“Pivoting to New Paths – Charting a New Way Forward,” ASCO Professional Development Series for Women in Oncology, November 14, 2023, Virtual
 - m. Women In Oncology Panel, Miami Breast Cancer Conference, Panelist & Co-**Chair**, Developed curriculum January – March 2024; Event and lectures March 7, 2024
 - n. National Fellows Forum—Breast Cancer, San Antonio Breast Cancer Symposium with OncLive, **Chair**, April 2024 - December 2024: *Developed curriculum, served as mentor to*

selected fellows; reviewed submitted abstracts; provided feedback on research concepts and presentations; network across 30 fellows to facilitate career development; presented to forum on career development.

- o. “Management Styles: Getting the Best Out of Your Team” Women’s Networking Center, American Society of Clinical Oncology Annual Meeting 2024, Chicago, IL, June 2, 2024
4. GRASP Scientist < > Advocate Poster Talk Program
GRASP (Guiding Researchers and Advocates to Scientific Partnerships) is a non-profit that works connecting patient advocates and conference attendees with senior advocates, clinicians and scientists to discuss poster presentations and critical appraisal of breaking science
- a. San Antonio Breast Cancer Symposium, 2019
 - b. American Society of Clinical Oncology, 2020
 - c. American Society of Clinical Oncology, 2022
 - d. American Society of Clinical Oncology, 2023
 - e. San Antonio Breast Cancer Symposium, 2023
 - f. American Society of Clinical Oncology, 2024

International Advising/Mentoring

- 1. American Society of Clinical Oncology 2024 International Development and Education Award (IDEA) Program Mentor
 - a. Dr. Mary Antonette Ong
Iloilo City, Philippines